

RÉFÉRENCES (édition parue en mai 2009)

Page (P.) 15 Paragraphe (par.): *Si vous lisez le...*

GREENE, R. A. et FELDON, L. *Perfect Balance*, New York, Clarkson Potter/Publisher, 2005, 351 p.

par.: *Si vous lisez les...*

LEE, J. R. *Équilibre hormonal et progestérone naturelle*, France, Éditions Sully, 2002, 174 p.

par.: *Paru en 2003, le...*

NORTHROP, C. *La sagesse de la ménopause*, Québec, Éditions AdA, 2003, 847 p.

P. 27 par.: *L'adrénopause se définit...*

MIGEON, C. J., KELLER, A. R., LAWRENCE, B. *et al.* « Dehydroepiandrosterone and androsterone levels in human plasma: Effect of age and sex; day-to-day and diurnal variations », *Journal of Clinical Endocrinology & Metabolism*, vol. 17, 1957, p. 1051-1062.

par.: *L'adrénopause et la...*

Revue dans Rebar, R.W. « Androgen therapy for aging men and women: Not ready yet », *Journal Watch General Medicine*, vol. 27, 2006, p. 1.

P. 28 par.: *De plus en plus...*

Document de référence du Collège des médecins du Québec et de l'Ordre des pharmaciens du Québec, *Les produits de santé naturels. Pour mieux conseiller vos patients*, octobre 2004, 24 p.

P. 29 par.: *Une lecture des articles...*

KRONENBERG, F. et FUGH-BERMAN, A. « Complementary and alternative medicine for menopausal symptoms: A review of randomized, controlled trials », *Annals of Internal Medicine*, vol. 137, 2002, p. 805-813.

par.: *Des articles scientifiques de synthèse...*

NEWTON K. M., REED, S. D., LACROIX, A. Z. *et al.* « Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: A randomized trial », *Annals of Internal Medicine*, vol. 145, 2006, p. 869-879.

NELSON, H. D., VESCO, K. K., HANEY, E. *et al.* « Nonhormonal therapies for menopausal hot flashes: Systematic review and meta-analysis », *The Journal of the American Medical Association*, vol. 295, 2006, p. 2057-2071.

STEINBERG, W. M. « Nonhormone choices for menopausal symptoms. Vasomotor hot flashes and flushes », *Patient care*, juin 2006, p. 41, 44-45.

TICE, J. A. et GRADY, D. « Alternatives to estrogen for treatment of hot flashes: Are they effective and safe? », *The Journal of the American Medical Association*, vol. 295, 2006, p. 2076-2078.

par.: *Une étude a porté...*

NEWTON, K. M., REED, S. D., LACROIX, A. Z. *et al.* « Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: A randomized trial », *Annals of Internal Medicine*, vol. 145, 2006, p. 869-879.

P. 31 par.: *Récemment, deux méta-analyses des...*

NELSON, H. D., VESCO, K. K., HANEY, E. *et al.* « Nonhormonal therapies for menopausal hot flashes: Systematic review and meta-analysis », *The Journal of the American Medical Association*, vol. 295, 2006, p. 2057-2071.

TICE, J. A. et GRADY, D. « Alternatives to estrogen for treatment of hot flashes: Are they effective and safe? », *The Journal of the American Medical Association*, vol. 295, 2006, p. 2076-2078.

P. 34 par.: *Néanmoins, les femmes ne...*

GORMAN, B. K. et GHAZAL READ, J. « Why men die younger than women », *Geriatrics and aging*, vol. 10, 2007, p. 179-181.

par.: *N'oublions pas qu'au...*

GORMAN, B. K. et GHAZAL READ, J. « Why men die younger than women » *Geriatrics and aging*, vol. 10, 2007, p. 179-181.

P. 37 par.: *Le 20 juillet 2001...*

GERSON, M. et KUTTENN, F. « Enjeux et perspectives du traitement de la ménopause. Une femme, un traitement hormonal substitutif? », *Les sélections de médecine/sciences*, n° 16, 2001, p. 5-12.

P. 39 par.: *Les ECE (estrogènes conjugués...*

FRASER, I. S., JANSEN, R. P. S., LOBO, R. A. *et al.* *Estrogens and Progestogens in Clinical Practice*, New York, Churchill Livingstone, 1998, 928 p.

SPEROFF, L., GLASS, R. H. et KASE, N. G. *Clinical Gynecologic Endocrinology and Infertility*, 6^e édition, Baltimore, Lippincott-Williams & Wilkins, 1999, 727 p.

par.: *Dans les ECE, environ...*

FRASER, I. S., JANSEN, R. P. S., LOBO, R. A. *et al.* *Estrogens and Progestogens in Clinical Practice*, New York, Churchill Livingstone, 1998, 928 p.

NACHTIGALL, L. E., RAJU, U., BANERJEE, S. *et al.* « Serum estradiol-binding profiles in postmenopausal women undergoing three common estrogen replacement therapies: Associations with sex hormone-binding globulin, estradiol, and estrone levels », *Menopause*, vol. 7, 2000, p. 243-250.

par.: *Au contraire, non seulement...*

LINDOFF, C., PETERSON, F., LECANDER, I. *et al.* « Transdermal estrogen replacement therapy: Beneficial effects on hemostatic risk factors for cardiovascular disease », *Maturitas*, vol. 24, 1996, p. 43-50.

SCARABIN, P.-Y., ALHENC-GELAS, M., PLU-BUREAU, G. *et al.* « Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial », *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 17, 1997, p. 3071-3078.

BONDUKI, C. E., LOURENÇO, DM., BARACAT, E. *et al.* « Effect of estrogen-progestin hormonal replacement therapy on plasma antithrombin III of postmenopausal women », *Acta Obstetricia et Gynecologica Scandinavica*, vol. 77, 1998, p. 330-333.

SCARABIN, P.Y., OGER, E. et PLU-BUREAU, G. « Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk », *Lancet* vol. 362, 2003, p. 428-432.

P. 42 par.: *En mai 2002, ce...*

Writing Group for the Women's Health Initiative Investigators. « Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial », *The Journal of the American Medical Association*, vol. 288, 2002, p. 321-333.

P. 44 par.: *Une analyse des résultats...*

PRENTICE, R. L., LANGER, R. D., STEFANICK, M. L. *et al.* « Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease », *American Journal of Epidemiology*, vol. 163, 2006, p. 589-599.

ROSSOUW, J. E., PRENTICE, R. L., MANSON, J. E. *et al.* « Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause », *The Journal of the American Medical Association*, vol. 297, 2007, p. 1465-1477.

par.: *Il est intéressant de...*

ROSSOUW, J. E., PRENTICE, R. L., MANSON, J. E. *et al.* « Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause », *The Journal of the American Medical Association*, vol. 297, 2007, p. 1465-1477.

par.: *Ensuite, il est important...*

MASTORAKOS, G., SAKKAS, E. GR., XYDAKIS, A. M. *et al.* « Pitfalls of the WHIs. Women's Health Initiative », *New York Academy of Sciences*, vol. 1092, 2006, p. 331-340.

P. 45 par.: *Finalement, commencer l'hormonothérapie...*

PRENTICE, R. L., LANGER, R. D., STEFANICK, M. L. *et al.* « Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease », *American Journal of Epidemiology*, vol. 163, 2006, p. 589-599.

ROSSOUW, J. E., PRENTICE, R. L., MANSON, J. E. *et al.* « Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause », *The Journal of the American Medical Association*, vol. 297, 2007, p. 1465-1477.

par.: *Peu de gens sont...*

The Women's Health Initiative Steering Committee. « Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial », *The Journal of the American Medical Association*, vol. 291, 2004, p. 1701-1712.

P. 47 par.: *Nous observons pourtant que...*

The Women's Health Initiative Steering Committee. « Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial », *The Journal of the American Medical Association*, vol. 291, 2004, p. 1701-1712.

- P. 50 par.: *Ces observations sont en...*
GRADY, D., WENGER, N. K., HERRINGTON, D. *et al.* « Postmenopausal hormone therapy increases risk for venous thromboembolic disease: The Heart and Estrogen/Progestin Replacement Study », *Annals of Internal Medicine*, vol. 132, 2000, p. 689-696.
- P. 51 par.: *Il est pertinent de...*
HANLEY, D. A. et JOSSE, R. G. « Prevention and management of osteoporosis: Consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada », *Canadian Medical Association Journal*, vol. 155, 1996, p. 921-922.
- P. 52 par.: *Par exemple, le risque...*
REID, L. et LEMAY, A. « Un mauvais service – Il est regrettable que la Société canadienne du cancer n’ait pas étudié plus à fond la population de femmes à laquelle elle s’est adressée », *La Presse*, 20 janvier 2004, p. A-11.
- P. 53 par.: *Il est important de...*
GRADY, D., WENGER, N. K., HERRINGTON, D. *et al.* « Postmenopausal hormone therapy increases risk for venous thromboembolic disease: The Heart and Estrogen/Progestin Replacement Study », *Annals of Internal Medicine*, vol. 132, 2000, p. 689-696.
- P. 58 par.: *Si vous faites une...*
Heart and Stroke Foundation. *Women, heart disease and stroke*, HSFO, 2003.
par.: *Il y a environ...*
Revue dans MIYAGAWA, K., RÖSCH, J., STANCZYK, F. *et al.* « Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm », *Nature Medicine*, vol. 3, 1997, p. 324-327.
par.: *Parmi les maladies cardiovasculaires...*
MIKHAIL, G. W. « Coronary heart disease in women is underdiagnosed, undertreated, and under-researched », *British Medical Journal*, vol. 331, 2005, p. 467-468.
par.: *Il est actuellement connu...*
LERNER, D. J. et KANNEL, W. B. « Patterns of coronary heart disease morbidity and mortality in the sexes: A 26-year follow-up of the Framingham population », *American Heart Journal*, vol. 111, 1986, p. 383-390.
U.S. Department of health and human services. *National vital statistics report: U.S. Department of health and human services. Centers for disease control and prevention*, National Center for Health Statistics, National Vital Statistics System, 2002, 50 p.
par.: *Dans une étude...*
BAIREY MERZ, C. N., JOHNSON, B.D., SHARAF, B.L. *et al.* « Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: A report from the NHLBI-Sponsored WISE study », *Journal of the American College of Cardiology*, vol. 41, 2003, p. 413-419.
- P. 59 Tableau (tabl.): *Saviez-vous que...*
Revue dans BELCHETZ, P. E. « Hormonal treatment of postmenopausal women » *The New England Journal of Medicine*, vol. 330, 1994, p. 1062-1071.

- P. 60 par.: *Des chercheurs ont observé...*
- BAIREY MERZ, C. N., JOHNSON, B.D., SHARAF, B.L. *et al.* « Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: A report from the NHLBI-Sponsored WISE study », *Journal of the American College of Cardiology*, vol. 41, 2003, p. 413-419.
- par.: *Dans une étude randomisée...*
- HODIS, H. N., MACK, W. J., LOBO, R. A. *et al.* « Estrogen in the prevention of atherosclerosis », *Annals of Internal Medicine*, vol. 135, 2001, p. 939-953.
- par.: *Deux expériences chez des...*
- ADAMS, M. R., KAPLAN, J. R., MANUCK, S. B. *et al.* « Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone » *Arteriosclerosis*, vol. 10, 1990, p. 1051-1057.
- CLARKSON, T. B., SHIVELY, C. A., MORGAN, T. M. *et al.* « Oral contraceptives and coronary artery atherosclerosis of cynomolgus monkeys », *Obstetrics and Gynecology*, vol. 75, 1990, p. 217-222.
- par.: *Par ailleurs, si la...*
- CLARKSON, T. B., SHIVELY, C. A., MORGAN, T. M. *et al.* « Oral contraceptives and coronary artery atherosclerosis of cynomolgus monkeys », *Obstetrics and Gynecology*, vol. 75, 1990, p. 217-222.
- ADAMS, M. R., KAPLAN, J. R., MANUCK, S. B. *et al.* « Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone » *Arteriosclerosis*, vol. 10, 1990, p. 1051-1057.
- par.: *D'autres études chez...*
- ADAMS, M. R., KAPLAN, J. R., CLARKSON, T. B. *et al.* « Ovariectomy, social status, and atherosclerosis in cynomolgus monkeys », *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 5, 1985, p. 192-200.
- ADAMS, M. R., KAPLAN, J. R., KORITNIK, D. R. *et al.* « Pregnancy-associated inhibition of coronary artery atherosclerosis in monkeys. Evidence of a relationship with endogenous estrogen », *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 7, 1987, p. 378-384.
- P. 61 par.: *À la ménopause, malheureusement...*
- JENSEN, J., NILAS, L. et CHRISTIANSEN, C. « Influence of menopause on serum lipids and lipoproteins », *Maturitas*, vol. 12, 1990, p. 321-331.
- STEVENSON, J. C., CROOK, D., GODSLAND, I. F. « Influence of age and menopause on serum lipids and lipoproteins in healthy women », *Atherosclerosis*, vol. 98, 1993, p. 83-90.
- par.: *L'étude PEPI (Postmenopausal...*
- The Writing Group for the PEPI trial. « Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial », *The Journal of the American Medical Association*, vol. 273, 1995, p. 199-208.
- P. 62 par.: *Cependant, il est important...*
- BASDEVANT, A., DE LIGNIERES, B. et GUY-GRAND, B. « Differential lipemic and hormonal responses to oral and parenteral 17 beta-estradiol in postmenopausal women », *American Journal of Obstetrics and Gynecology*, vol. 147, 1983, p. 77-81.

BUSH, T. L. et MILLER, V. T. « Effects of pharmacologic agents used during menopause : Impact on lipids and lipoproteins », dans D. R. MISHALL (dir.). *Menopause : Physiology and pharmacology*, Chicago, Year Book Medical, 1987, p. 187-208.

CROOK, D., CUST, M. P., GANGAR, K. F. *et al.* « Comparison of transdermal and oral estrogen-progestin replacement therapy: Effects on serum lipids and lipoproteins », *American Journal of Obstetrics and Gynecology*, vol. 166, 1992, p. 950-955.

PAGANINI-HILL, A., DWORSKY, R. et KRAUSS, R. M. « Hormone replacement therapy, hormone levels, and lipoprotein cholesterol concentrations in elderly women », *American Journal of Obstetrics and Gynecology*, vol. 174, 1996, p. 897-902.

ERENUS, M., KARAKOÇ, B. et GÜRLER, A. « Comparison of effects of continuous combined transdermal with oral estrogen and oral progestogen replacement therapies on serum lipoproteins and compliance », *Climacteric*, vol. 4, 2001, p. 228-234.

WEST, S. G., HINDERLITER, A. L., WELLS, E. C. *et al.* « Transdermal estrogen reduces vascular resistance and serum cholesterol in postmenopausal women », *American Journal of Obstetrics and Gynecology*, vol. 184, 2001, p. 926-933.

P. 62 par.: *Dans une étude chez...*

ERENUS, M., KARAKOÇ, B. et GÜRLER, A. « Comparison of effects of continuous combined transdermal with oral estrogen and oral progestogen replacement therapies on serum lipoproteins and compliance », *Climacteric*, vol. 4, 2001, p. 228-234.

par.: *L'estradiol-17β a contribué...*

ADAMS, M. R., KAPLAN, J. R., MANUCK, S. B. *et al.* « Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone », *Arteriosclerosis*, vol. 10, 1990, p. 1051-1057.

P. 63 par.: *Il existe plusieurs marqueurs...*

RIDKER, P. M., HENNEKENS, C. H., BURING, J. E. *et al.* « C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women », *The New England Journal of Medicine*, vol. 342, 2000, p. 836-843.

DECENSI, A., OMODEI, U., ROBERTSON, C. *et al.* « Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women », *Circulation*, vol. 106, 2002, p. 1224-1228.

Revue dans MODENA, M. G., BURSI, F., FANTINI, G. *et al.* « Effects of hormone replacement therapy on C-reactive protein levels in healthy postmenopausal women: Comparison between oral and transdermal administration of estrogen », *The American Journal of Medicine*, vol. 113, 2002, p. 331-334.

tabl.: *Un taux élevé de...*

RIDKER, P. M., HENNEKENS, C. H., BURING, J. E. *et al.* « C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women », *The New England Journal of Medicine*, vol. 342, 2000, p. 836-843.

par.: *Un lien direct est...*

CERMAK, J., KEY, N. S., BACH, R. R. *et al.* « C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor », *Blood*, vol. 82, 1993, p. 513-520.

GALVE-DE ROCHEMONTEIX, B., WIKTOROWICZ, K., KUSHNER, I. *et al.* « C-reactive protein increases production of IL-1 alpha, IL-1 beta, and TNF-alpha, and expression of mRNA by human alveolar macrophages », *Journal of Leukocyte Biology*, vol. 53, 1993, p. 439-445.

TORZEWSKI, J., BOWYER, D. E., WALTENBERGER, J. *et al.* « Processes in atherogenesis: Complement activation », *Atherosclerosis*, vol. 132, 1997, p. 131-138.

PASCERI, V., WILLERSON, J. T. et YEH, E. T. H. « Direct proinflammatory effect of C-reactive protein on human endothelial cells », *Circulation*, vol. 102, 2000, p. 2165-2168.

TORZEWSKI, M., RIST, C., MORTENSEN, R. F. *et al.* « C-reactive protein in the arterial intima: Role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis », *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 20, 2000, p. 2094-2099.

par.: *Des chercheurs ont observé...*

VAN BAAL, W. M., KENEMANS, P., VAN DER MOOREN, M. J. *et al.* « Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women », *Thrombosis and Haemostasis*, vol. 81, 1999, p. 925-928.

DECENSI, A., OMODEI, U., ROBERTSON, C. *et al.* « Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women », *Circulation*, vol. 106, 2002, p. 1224-1228.

MODENA, M. G., BURSI, F., FANTINI, G. *et al.* « Effects of hormone replacement therapy on C-reactive protein levels in healthy postmenopausal women: Comparison between oral and transdermal administration of estrogen », *The American Journal of Medicine*, vol. 113, 2002, p. 331-334.

VONGPATANASIN, W., TUNCEL, M., WANG, Z. *et al.* « Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women », *Journal of the American College of Cardiology*, vol. 41, 2003, p. 1358-1363.

par.: *Au contraire, l'estradiol-17β...*

NUNOMURA, W., TAKAKUWA, Y. et HIGASHI, T. « Changes in serum concentration and mRNA level of rat C-reactive protein », *Biochimica et Biophysica Acta*, vol. 1227, 1994, p. 74-78.

VONGPATANASIN, W., TUNCEL, M., WANG, Z. *et al.* « Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women », *Journal of the American College of Cardiology*, vol. 41, 2003, p. 1358-1363.

SATTAR, N., PERERA, M., SMALL, M. *et al.* « Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes », *Lancet*, vol. 354, 1999, p. 487-488.

P. 65 par.: *En médecine, il est...*

KESSLER, K. M. « Syndrome X: The epicardial view », *Journal of the American College of Cardiology*, vol. 19, 1992, p. 32-33.

KASKI, J. C., ROSANO, G. M. C., COLLINS, P. *et al.* « Cardiac syndrome X: Clinical characteristics and left ventricular function. Long-term follow-up study », *Journal of the American College of Cardiology*, vol. 25, 1995, p. 807-814.

par.: *Selon des chercheurs, une...*

BAIREY, C. N. « WISE study », *Journal of the American College of Cardiology* (supplément de *Cardiology*), 7 février 2006.

par.: *Plusieurs études ont montré...*

revue dans VANE, J. R., ANGGARD, E. E. et BOTTING, R. M. « Regulatory functions of the vascular endothelium », *The New England Journal of Medicine*, vol. 323, 1990, p. 27-36.

par.: *Chez les femmes atteintes...*

COLLINS, P., ROSANO, G. M. C., SARREL, P. M. *et al.* « 17 β -estradiol attenuates acetylcholine induced coronary arterial constriction in women but not men with coronary heart disease », *Circulation*, vol. 92, 1995, p. 24-30.

par.: *Des chercheurs ont observé...*

ROSANO, G. M. C., SARREL, P. M., POOLE-WILSON, P. A. *et al.* « Beneficial effect of oestrogen on exercise-induced myocardial ischemia in women with coronary artery disease », *Lancet*, vol. 342, 1993, p. 133-136.

par.: *On connaît la nitroglycérine...*

Revue dans ROSANO, G. M. C., SARREL, P. M., POOLE-WILSON, P. A. *et al.* « Beneficial effect of oestrogen on exercise-induced myocardial ischemia in women with coronary artery disease », *Lancet*, vol. 342, 1993, p. 133-136.

P. 66 par.: *Des recherches chez des...*

WILLIAMS, J. K., HONORÉ, E. K., WASHBURN, S. A. *et al.* « Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys », *Journal of the American College of Cardiology*, vol. 24, 1994, p. 1757-1761.

MISHRA, R. G., HERMSMEYER, R. K., MIYAGAWA, K. *et al.* « Medroxyprogesterone acetate and dihydrotestosterone induce coronary hyperreactivity in intact male rhesus monkeys », *Journal of Clinical Endocrinology & Metabolism*, vol. 90, 2005, p. 3706-3714.

MIYAGAWA, K., RÖSCH, J., STANCZYK, F. *et al.* « Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm », *Nature Medecine*, vol. 3, 1997, p. 324-327.

par.: *Une étude réalisée chez...*

ROSANO, G. M. C., WEBB, C. M., CHIERCHIA, S. *et al.* « Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women », *Journal of the American College of Cardiology*, vol. 36, 2000, p. 2154-2159.

par.: *Par exemple, dans une...*

MATHER, K. J., NORMAN, E. G., PRIOR, J. C. *et al.* « Preserved forearm endothelial responses with acute exposure to progesterone: A randomized cross-over trial of 17- β estradiol, progesterone, and 17- β estradiol with progesterone in healthy menopausal women », *Journal of Clinical Endocrinology & Metabolism*, vol. 85, 2000, p. 4644-4649.

par.: *Des études chez des...*

HERMSMEYER, R. K., MISHRA, R. G., PAVCNIK, D. *et al.* « Atherosclerosis and lipoproteins. Prevention of coronary hyperreactivity in preatherogenic menopausal rhesus monkeys by transdermal progesterone », *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 24, 2004, p. 955-961.

JIANG, C., SAREL, P. M., LINDSAY, D. C. *et al.* « Progesterone induces endothelium-independent relaxation of rabbit coronary artery in vitro », *European Journal of Pharmacology*, vol. 211, 1992, p. 163-167.

- P. 67 par.: *Il est important de...*
MASTORAKOS, G., SAKKAS, E. GR., XYDAKIS, A. M. *et al.* « Pitfalls of the WHIs. Women's Health Initiative », *New York Academy of Sciences*, vol. 1092, 2006, p. 331-340.
- P. 68 par.: *Par exemple, le risque...*
JICK, H., JICK, S.S., GUREWICH, V. *et al.* « Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestagen components », *Lancet*, vol. 346, 1995, p. 1589-1593.
SEAMAN, H. E., DE VRIES, C. S. et FARMER, R.D.T. « Venous thromboembolism associated with cyproterone acetate in combination with ethinyloestradiol (Dianette®): Observational studies using the UK General Practice Research Database », *Pharmacoepidemiology and Drug Safety*, vol. 13, 2004, p. 427-436.
- P. 69 par.: *Plusieurs études ont montré...*
LINDOFF, C., PETERSON F., LECANDER, I. *et al.* « Transdermal estrogen replacement therapy: Beneficial effects on hemostatic risk factors for cardiovascular disease », *Maturitas*, vol. 24, 1996, p. 43-50.
SCARABIN, P. Y., ALHENC-GELAS, M., PLU-BUREAU, G. *et al.* « Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial », *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 17, 1997, p. 3071-3078.
BONDUKI, C. E., LOURENÇO, D. M., BARACAT, E. *et al.* « Effect of estrogen-progestin hormonal replacement therapy on plasma antithrombin III of postmenopausal women », *Acta Obstetrica et Gynecologica Scandinavica*, vol. 77, 1998, p. 330-333.
par.: *De plus, les estrogènes...*
GEBARA, O. C. E., MITTLEMAN, M. A., SUTHERLAND, P. *et al.* « Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring study », *Circulation*, vol. 91, 1995, p. 1952-1958.
MORALES, D. E., MCGOWAN, K. A., GRANT, D. S. *et al.* « Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model », *Circulation*, vol. 91, 1995, p. 755-763.
DE MITRIO, V., MARINO, R., CICINELLI, E. *et al.* « Beneficial effects of postmenopausal hormone replacement therapy with transdermal estradiol on sensitivity to activated protein C », *Blood Coagulation & Fibrinolysis*, vol. 11, 2000, p. 175-182.
FALCO, C., TORMO, G., ESTELLÉS, A. *et al.* « Fibrinolysis and lipoprotein (a) in women with coronary artery disease. Influence of hormone replacement therapy », *Haematologica*, vol. 86, 2001, p. 92-98.
par.: *Il est intéressant de...*
CHAMBERS, J. C., MCGREGOR, A., JEAN-MARIE, J. *et al.* « Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: An effect reversible with vitamin C therapy », *Circulation*, vol. 99, 1999, p. 1156-1160.
NAPPO, F., DE ROSA, N., MARFELLA, R. *et al.* « Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins », *The Journal of the American Medical Association*, vol. 281, 1999, p. 2113-2118.

MIJATOVIC, V., KENEMANS, P., JAKOBS, C. *et al.* « A randomized controlled study of the effects of 17 beta-estradiol-dydrogesterone on plasma homocysteine in postmenopausal women », *Obstetrics & Gynecology*, vol. 91, 1998, p. 432-436.

MIJATOVIC, V., KENEMANS, P., NETELENBOS, C. *et al.* « Postmenopausal oral 17beta-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels », *Fertility and Sterility*, vol. 69, 1998, p. 876-882.

KALELI, B., YILDIRIM, B., DEMIR, S. *et al.* « Effects of low-dose 17- β -estradiol plus norethisterone acetate and tibolone on fasting plasma homocysteine levels in postmenopausal women », *Acta Obstetrica et Gynecologica Scandinavica*, vol. 82, 2003, p. 1107-1111.

par.: *En 2003, dans une...*

SCARABIN, P. Y., OGER, E. et PLU-BUREAU, G. « Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk », *Lancet*, vol. 362, 2003, p. 428-432.

P. 70 par.: *D'ailleurs, le risque...*

WENGER, N. K., SPEROFF, L. et PACKARD, B. « Cardiovascular health and disease in women », *The New England Journal of Medicine*, vol. 329, 1993, p. 247-256.

tabl.: *L'estradiol-17 β , les statines...*

GRADY, D., WENGER, N. K., HERRINGTON, D. *et al.* « Postmenopausal hormone therapy increases risk for venous thromboembolic disease: The Heart and Estrogen/Progestin Replacement Study », *Annals of Internal Medicine*, vol. 132, 2000, p. 689-696.

ALBERT, M. A., DANIELSON, E., RIFAI, N. *et al.* « Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study », *The Journal of the American Medical Association*, vol. 286, 2001, p. 64-70.

P. 72 tabl.: *Qu'est-ce que l'étude WHIMS*

SHUMAKER, S. A., LEGAULT, C., RAPP, S. R. *et al.* « Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women's Health Initiative Memory Study: A randomized controlled trial », *The Journal of the American Medical Association*, vol. 289, 2003, p. 2651-2662.

par.: *Selon le Dr Barbara...*

SHERWIN, B. Entrevue dans *L'Actualité médicale*, 2004.

par.: *Un bon article synthèse...*

GIBBS, R. B. et GABOR, R. « Estrogen and cognition: Applying preclinical findings to clinical perspectives », *Journal of Neuroscience Research*, vol. 74, 2003, p. 637-643.

tabl.: *Saviez-vous que...*

Groupe de travail de l'Étude canadienne sur la santé et le vieillissement: Méthodes d'étude et prévalence de la démence. *The Journal of the American Medical Association*, vol. 150, 1994, p. 899-913.

P. 73 par.: *Les résultats ont montré...*

ZANDI, P. P., CARLSON, M. C., PLASSMAN, B. L. *et al.* « Hormone replacement therapy and incidence of Alzheimer disease in older women. The Cache County Study », *The Journal of the American Medical Association*, vol. 288, 2002, p. 2123-2129.

par.: *Une étude avait déjà...*

MULNARD, R. A., COTMAN, C. W., KAWAS, C. *et al.* « Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial. Alzheimer's Disease Cooperative Study », *The Journal of the American Medical Association*, vol. 283, 2000, p. 1007-1015.

par.: *Des chercheurs ont émis...*

Revue dans BRINTON, R. D. « Investigative models for determining hormone therapy-induced outcomes in brain. Evidence in support of a healthy cell bias of estrogen action », *Annals of the New York Academy of Sciences*, vol. 1052, 2005, p. 57-74.

P. 74 par.: *L'estradiol-17 β exerce un effet vasodilatateur...*

PENOTTI, M., SIRONI, L., MIGLIERINA, L. *et al.* « The effect of tamoxifen and transdermal 17 β -estradiol on cerebral arterial vessels: A randomized controlled study », *American Journal of Obstetrics and Gynecology*, vol. 178, 1998, p. 801-805.

GREENE, R. A. et FELDON, L. *Perfect Balance*, New York, Clarkson Potter/Publisher, 2005, 351 p.

par.: *L'estradiol-17 β exerce un effet protecteur...*

GREEN, P. S., BISHOP, J., SIMPKINS, J. W. « 17 β -estradiol exerts neuroprotective effects on SK-N-SH cells », *The Journal of Neuroscience*, vol. 17, 1997, p. 511-515.

MOORADIAN, A. D. « Antioxidant properties of steroids », *The Journal of Steroid Biochemistry and Molecular Biology*, vol. 45, 1993, p. 509-511.

BEHL, C., SKUTELLA, T., LEZOUALC'H, F. *et al.* « Neuroprotection against oxidative stress by estrogens: Structure-activity relationship », *Molecular Pharmacology*, vol. 51, 1997, p. 535-541.

MOOSMANN, B. et BEHL, C. « The antioxidant neuroprotective effects of estrogens and phenolic compounds are independent from their estrogenic properties », *Proceedings of the National Academy of Sciences of the United States of America*, vol. 96, 1999, p. 8867-8872.

NILSEN, J. et BRINTON, R. D. « Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling », *Proceedings of the National Academy of Sciences*, vol. 100, 2003, p. 10506-10511.

Revue dans BROWER, V. « A second chance for hormone replacement therapy? », *European Molecular Biology Organization*, vol. 4, 2003, p. 1112-1115.

par.: *L'estradiol-17 β exerce un effet trophique...*

NAFTOLIN, F., GARCIA-SEGURA, L. M., KEEFE, D. *et al.* « Estrogen effects on the synaptology and neural membranes of the rat hypothalamic arcuate nucleus », *Biology of Reproduction*, vol. 42, 1990, p. 21-28.

WOOLLEY, C. S., WEILAND, N. G., McEWEN, B. S. *et al.* « Estradiol increases the sensitivity of hippocampal CA1 pyramidal cells to NMDA receptor-mediated synaptic input: Correlation with dendritic spine density », *The Journal of Neuroscience*, vol. 17, 1997, p. 1848-1859.

GARCIA-SEGURA, L. M., NAFTOLIN, F., HUTCHISON, J. B. *et al.* « Role of astroglia in estrogen regulation of synaptic plasticity and brain repair », *Journal of Neurobiology*, vol. 40, 1999, p. 574-584.

BRINTON, R. D. « Cellular and molecular mechanisms of estrogen regulation of memory function and neuroprotection against Alzheimer's disease: Recent insights and remaining challenges », *Learning & Memory*, vol. 8, 2001, p. 121-133.

GENAZZANI, A. R., PLUCHINO, N., LUISI, S. *et al.* « Estrogen, cognition and female ageing », *Human Reproduction Update*, vol. 13, 2007, p. 175-187.

par. : *Par exemple, des analyses...*

BRINTON, R.D., TRAN, J., PROFITT, P. *et al.* « 17β -estradiol increases the growth and survival of cultured cortical neurons », *Neurochem. Res.*, vol. 22, 1997, p. 1339-1351.

BRINTON, R. D., CHEN, S., MONTOYA, M. *et al.* « The women's health initiative estrogen replacement therapy is neurotrophic and neuroprotective », *Neurobiology of Aging*, vol. 21, 2000, p. 475-496.

WOOLLEY, C. S., WEILAND, N. G., McEWEN, B. S. *et al.* « Estradiol increases the sensitivity of hippocampal CA1 pyramidal cells to NMDA receptor-mediated synaptic input : Correlation with dendritic spine density », *The Journal of Neuroscience*, vol. 17, 1997, p. 1848-1859.

P. 75 par. : *Chez les animaux, un...*

Revue dans GIBBS, R. B. et GABOR, R. « Estrogen and cognition : Applying preclinical findings to clinical perspectives », *Journal of Neuroscience Research*, vol. 74, 2003, p. 637-643.

SINGH, M., MEYER, E. M., MILLARD, W. J. *et al.* « Ovarian steroid deprivation results in a reversible learning impairment and compromised cholinergic function in female Sprague-Dawley rats », *Brain Research*, vol. 644, 1994, p. 305-312.

DANIEL, J. M., HULST, J. L. et BERBLING, J. L. « Estradiol replacement enhances working memory in middle-aged rats when initiated immediately after ovariectomy but not after a long-term period of ovarian hormone deprivation », *Endocrinology*, vol. 147, 2006, p. 607-614.

par. : *On sait que les...*

PHILLIPS, S. M. et SHERWIN, B. B. « Variations in memory function and sex steroid hormones across the menstrual cycle », *Psychoneuroendocrinology*, vol. 17, 1992, p. 497-506.

PHILLIPS, S. M. et SHERWIN B. B. « Effects of estrogen on memory function in surgically menopausal women », *Psychoneuroendocrinology*, vol. 17, 1992, p. 485-495.

KAMPEN, D. L. et SHERWIN, B. B. « Estrogen use and verbal memory in healthy postmenopausal women », *Obstetrics & Gynecology*, vol. 83, 1994, p. 979-983.

SHERWIN, B. B. et TULANDI, T. « "Add-back" estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri », *Journal of Clinical Endocrinology & Metabolism*, vol. 81, 1996, p. 2545-2549.

SHERWIN, B. B. « Estrogen and cognitive aging in women », *Trends in Pharmacological Sciences*, vol. 23, 2002, p. 527-534.

par. : *De façon concordante, une...*

GRIGOROVA, M., SHERWIN, B. B. et TULANDI, T. « Effects of treatment with leuprolide acetate depot on working memory and executive functions in young premenopausal women », *Psychoneuroendocrinology*, vol. 31, 2006, p. 935-947.

par. : *Chez des hommes ayant...*

SALMINEN, E. K., PORTIN, R. I., KOSKINEN, A. I. *et al.* « Estradiol and cognition during androgen deprivation in men with prostate carcinoma », *Cancer*, vol. 103, 2005, p. 1381-1387.

par. : *À la ménopause, le...*

GREENE, R. A. et FELDON, L. *Perfect Balance*, New York, Clarkson Potter/Publisher, 2005, 351 p.

par.: *Par exemple, les femmes...*

Groupe de travail de l'Étude canadienne sur la santé et le vieillissement: Méthodes d'étude et prévalence de la démence, *The Journal of the American Medical Association*, 1994, vol. 150, p. 899-913.

par.: *Des recherches chez des...*

YUE, X., LU, M., LANCASTER, T. *et al.* « Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model », *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, 2005, p. 19198-19203.

P. 76 par.: *Dans les neurones corticaux...*

XU, H., GOURAS, G.K., GREENFIELD, J.-P. *et al.* « Estrogen reduces neuronal generation of Alzheimer β -amyloid peptides », *Nature Medicine*, vol. 4, 1998, p. 447-451.

YUE, X., LU, M., LANCASTER, T. *et al.* « Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model », *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, 2005, p. 19198-19203.

par.: *Dans une étude chez...*

FILLIT, H., WEINREB, H., CHOLST, I. *et al.* « Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type », *Psychoneuroendocrinology*, vol. 11, 1986, p. 337-345.

BRINTON, R. D. « Investigative models for determining hormone therapy-induced outcomes in brain. Evidence in support of a healthy cell bias of estrogen action », *Annals of the New York Academy of Sciences*, vol. 1052, 2005, p. 57-74.

P. 77 par.: *En conclusion, l'estradiol-17 β ...*

GENAZZANI, A. R., PLUCHINO, N., LUISI, S. *et al.* « Estrogen, cognition and female ageing », *Human Reproduction Update*, vol. 13, 2007, p. 175-187.

SUZUKI, S., BROWN, C. M., DELA CRUZ, C. D. *et al.* « Timing of estrogen therapy after ovariectomy dictates the efficacy of its neuroprotective and antiinflammatory actions », *Proceedings of the National Academy of Sciences*, vol. 104, 2007, p. 6013-6018.

P. 78 par.: *À ce jour, les...*

COOPE, J., THOMSON, J. M. et POLLER, L. « Effects of "natural oestrogen" replacement therapy on menopausal symptoms and blood clotting », *British Medical Journal*, vol. 4, 1975, p. 139-143.

STRICKLER, R. C., BORTH, R., CECUTTI, A. *et al.* « The role of oestrogen replacement in the climacteric syndrome », *Psychological Medicine*, vol. 7, 1977, p. 631-639.

THOMPSON, J. et OSWALD, I. « Effect of oestrogen on the sleep, mood, and anxiety of menopausal women », *British Medical Journal*, vol. 2, 1977, p. 1317-1319.

par.: *Dans une étude à...*

DE NOVAES SOARES, C., ALMEIDA, O. P., JOFFE, H. *et al.* « Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women », *Archives of General Psychiatry*, vol. 58, 2001, p. 529-534.

par.: *L'estradiol-17 β réduit les...*

SCHMIDT, P. J., NIEMAN, L., DANACEAU, M. A. *et al.* « Estrogen replacement in perimenopause-related depression: A preliminary report », *American Journal of Obstetrics and Gynecology*, vol. 183, 2000, p. 414-420.

par.: *Dans une étude à...*

GREGOIRE, A. J. P., KUMAR, R., EVERITT, B. *et al.* « Transdermal oestrogen for treatment of severe postnatal depression », *Lancet*, vol. 347, 1996, p. 930-933.

tabl.: *L'efficacité des antidépresseurs...*

THASE, M. E., ENTSUAH, A.H. et RUDOLPH, R.I. « Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors », *The British Journal of Psychiatry*, vol. 178, 2001, p. 234-241.

par.: *En effet, des chercheurs...*

ROMEO, E., STRÖHLE, A., SPALLETTA, G. *et al.* « Effects of antidepressant treatment on neuroactive steroids in major depression », *The American Journal of Psychiatry*, vol. 155, 1998, p. 910-913.

UZUNOVA, V., SHELINE, Y., DAVIS, J. M. *et al.* « Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine », *Proceedings of the National Academy of Sciences of the United States of America*, vol. 95, 1998, p. 3239-3244.

STRÖHLE, A., ROMEO, E., HERMANN, B. *et al.* « Concentrations of 3 alpha-reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery », *Biological Psychiatry*, vol. 45, 1999, p. 274-277.

par.: *Une étude rigoureuse chez...*

HARLOW, B. L., COHEN, L.S., OTTO, M.W. *et al.* « Early life menstrual characteristics and pregnancy experiences among women with and without major depression: The Harvard study of moods and cycles », *Journal of Affective Disorders*, vol. 79, 2004, p. 167-176.

P. 79 par.: *Il est connu...*

Revue dans PECINS-THOMPSON, M. et BETHEA, C. L. « RU 486 blocks and fluoxetine augments progesterone-induced prolactin secretion in monkeys », *Neuroendocrinology*, vol. 65, 1997, p. 335-343.

P. 81 par.: *Premièrement, nous savons que...*

MAJEWSKA, M. D., HARRISON, N. L., SCHWARTZ, R. D. *et al.* « Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor », *Science*, vol. 232, 1986, p. 1004-1007.

Revue dans DEUTSCH, S.I., MASTROPAOLO, J. et HITRI, A. « GABA-active steroids: Endogenous modulators of GABA-gated chloride ion conductance », *Clinical Neuropharmacology*, vol. 15, 1992, p. 352-364.

MAGUIRE, J. et MODY, I. « Neurosteroid synthesis-mediated regulation of GABA_A receptors: Relevance to the ovarian cycle and stress », *The Journal of Neuroscience*, vol. 27, 2007, p. 2155-2162.

P. 82 par.: *Deuxièmement, l'allopregnanolone, en...*

TOUFEXIS, D.J., DAVIS, C., HAMMOND, A. *et al.* « Progesterone attenuates corticotropin-releasing factor-enhanced but not fear-potentiated startle via the activity of its neuroactive metabolite, allopregnanolone », *The Journal of Neuroscience*, vol. 24, 2004, p. 10280-10287.

tabl.: *Pour en savoir plus...*

PAZOL, K., WILSON, M. E. et WALLEN, K. « Medroxyprogesterone acetate antagonizes the effects of estrogen treatment on social and sexual behavior in female macaques », *Journal of Clinical Endocrinology & Metabolism*, vol. 89, 2004, p. 2998-3006.

P. 83 tabl.: *La progestérone est un...*

SCHUMACHER, M., ROBEL, P. et BAULIEU, E.-E. « Development and regeneration of the nervous system: A role for neurosteroids », *Developmental Neuroscience*, vol. 18, 1996, p. 6-21.

MELLON, S.H. et GRIFFIN, L.D. « Neurosteroids: Biochemistry and clinical significance », *Trends in endocrinology & metabolism*, vol. 13, 2002, p. 35-43.

MAGUIRE, J. et MODY, I. « Neurosteroid synthesis-mediated regulation of GABA_A receptors: Relevance to the ovarian cycle and stress », *The Journal of Neuroscience*, vol. 27, 2007, p. 2155-2162.

par.: *La progestérone exerce un...*

GOODMAN, Y., BRUCE, A. J., CHENG, B. *et al.* « Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons », *Journal of Neurochemistry*, vol. 66, 1996, p. 1836-1844.

ROOF, R. L., HOFFMAN, S. W. et STEIN, D. G. « Progesterone protects against lipid peroxidation following traumatic brain injury in rats », *Molecular and Chemical Neuropathology*, vol. 31, 1997, p. 1-11.

P. 84 par.: *Par contraste, des recherches...*

CIRIZA, I., CARRERO, P., FRYE, C. A. *et al.* « Reduced metabolites mediate neuroprotective effects of progesterone in the adult rat hippocampus. The synthetic progestin medroxyprogesterone acetate (Provera) is not neuroprotective », *Journal of Neurobiology*, vol. 66, 2006, p. 916-928.

par.: *L'administration de progestérone...*

CERVANTES, M., GONZÁLEZ-VIDAL, M. D., RUELAS, R. *et al.* « Neuroprotective effects of progesterone on damage elicited by acute global cerebral ischemia in neurons of the caudate nucleus », *Archives of Medical Research*, vol. 33, 2002, p. 6-14.

MURPHY, S. J., LITTLETON-KEARNEY, M. T. et HURN, P. D. « Progesterone administration during reperfusion, but not preischemic ovariectomized rats », *Journal Cerebral Blood Flow & Metabolism*, vol. 22, 2002, p. 1181-1188.

par.: *La progestérone a aussi...*

REGENSTEINER, J. G., WOODARD, W. D., HAGERMAN, D. D. *et al.* « Combined effects of female hormones and metabolic rate on ventilatory drives in women », *Journal of Applied Physiology*, vol. 66, 1989, p. 808-813.

PASCUAL, O., MORIN-SURUN, M.-P., BARNA, B. *et al.* « Progesterone reverses the neuronal responses to hypoxia in rat nucleus tractus solitarius in vitro », *Journal of Physiology*, vol. 544.2, 2002, p. 511-520.

par.: *Un autre effet positif...*

ROOF, R. L., DUVDEVANI, R., BRASWELL, L. *et al.* « Progesterone facilitates cognitive recovery and reduces secondary neuronal loss caused by cortical contusion injury in male rats », *Experimental Neurology*, vol. 129, 1994, p. 64-69.

ASBURY, E. T., FRITTS, M. E., HORTON, J.E. *et al.* « Progesterone facilitates the acquisition of avoidance learning and protects against subcortical neuronal death following prefrontal cortex ablation in the rat », *Behavioural Brain Research*, vol. 97, 1998, p. 99-106.

ROOF, R. L., DUVDEVANI, R. et STEIN, D. G. « Gender influences outcome of brain injury: Progesterone plays a protective role », *Brain Research*, vol. 607, 1993, p. 333-336.

VONGHER, J. M. et FRYE, C. A. « Progesterone in conjunction with estradiol has neuroprotective effects in an animal model of neurodegeneration », *Pharmacology Biochemistry and Behavior*, vol. 64, 1999, p. 777-785.

tabl. : *Pour en savoir plus...*

NILSEN, J. et BRINTON, R. D. « Impact of progestins on estradiol potentiation of the glutamate calcium response », *NeuroReport*, vol. 13, 2002, p. 825-830.

P. 85 par. : *De nombreuses études ont...*

Revue dans SCHUMACHER, M., ROBEL, P. et BAULIEU, E.-E. « Development and regeneration of the nervous system: A role for neurosteroids », *Developmental Neuroscience*, vol. 18, 1996, p. 6-21.

YU, W.-H. A. « Survival of motoneurons following axotomy is enhanced by lactation or by progesterone treatment », *Brain Research*, vol. 491, 1989, p. 379-382.

GONZALEZ DENISELLE, M. C., LÓPEZ-COSTA, J. J., GONZALEZ, S. L. *et al.* « Basis of progesterone protection in spinal cord neurodegeneration », *The Journal of Steroid Biochemistry and Molecular Biology*, vol. 83, 2002, p. 199-209.

GONZALEZ DENISELLE, M. C., LÓPEZ-COSTA, J. J., SAAVEDRA, J. P. *et al.* « Progesterone neuroprotection in the Wobbler mouse, a genetic model of spinal cord motor neuron disease », *Neurobiology of Disease*, vol. 11, 2002, p. 457-468.

par. : *La progestérogène est aussi...*

CHAN, J. R., RODRIGUEZ-WAITKUS, P. M., NG, B. K. *et al.* « Progesterone synthesized by Schwann cells during myelin formation regulates neuronal gene expression », *Molecular Biology of the Cell*, vol. 11, 2000, p. 2283-2295.

par. : *La progestérogène a aussi...*

HOFFMAN, G. E., MOORE, N., FISKUM, G. *et al.* « Ovarian steroid modulation of seizure severity and hippocampal cell death after kainic acid treatment », *Experimental Neurology*, vol. 182, 2003, p. 124-134.

ENSOM, M. H. H. « Gender-based differences and menstrual cycle-related changes in specific diseases: Implications for pharmacotherapy », *Pharmacotherapy*, vol. 30, 2000, p. 523-539.

FOLDVARY-SCHAEFER, N., HARDEN, C., HERZOG, A. *et al.* « Hormones and seizures », *Cleveland Clinic Journal of Medicine*, vol. 71, 2004, p. S11-S18.

P. 87 par. : *L'ostéoporose est une...*

MELTON, L. J., CHRISCHILLES, E. A., COOPER, C. *et al.* « Perspective: How many women have osteoporosis? », *Journal of Bone and Mineral Research*, vol. 7, 1992, p. 1005-1010.

P. 88 par. : *Peu de gens sont...*

HANLEY, D. A. et JOSSE, R. G. « Prevention and management of osteoporosis: Consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada », *Canadian Medical Association Journal*, vol. 155, 1996, p. 921-922.

par.: À la ménopause, la...

GREENSPAN, S. L., MAITLAND, L. A., MYERS, E. R. *et al.* « Femoral bone loss progresses with age: A longitudinal study in women over age 65 », *Journal of Bone and Mineral Research*, vol. 9, 1994, p. 1959-1965.

RAISZ, L. G. et PRESTWOOD, K. M. « Estrogen and the risk of fracture - new data, new questions », *The New England Journal of Medicine*, vol. 339, 1998, p. 767-768.

P. 89 tabl.: Avez-vous besoin de...

BROWN, J. P. et JOSSE R.G. « Lignes directrices de pratique clinique 2002 pour le diagnostic et le traitement de l'ostéoporose au Canada », *Journal de l'Association Médicale du Canada*, vol. 168 (suppl. 6), 2003, p. SF1-SF38.

BRAULT DUBUC, M. et CARON LAHAIE, L. Valeur nutritive des aliments, 9^e édition, Société Brault-Lahaie, 331 p.

par.: Certains croient que le...

FINKELSTEIN, J. S. « Calcium plus vitamin D for postmenopausal women-Bone appétit? », *The New England Journal of Medicine*, vol. 354, 2006, p. 750-752.

par.: Une sous-étude de la...

JACKSON, R. D., LACROIX, A. Z., GASS, M. *et al.* « Calcium plus vitamine D supplementation and the risk of fractures », *The New England Journal of Medicine*, vol. 354, 2006, p. 669-683.

P. 90 tabl.: La diminution de...

YANG, Y. X., LEWIS, J. D., EPSTEIN, S. *et al.* « Long-term proton pump inhibitor therapy and risk of hip fracture », *The Journal of the American Medical Association*, vol. 296, 2006, p. 2947-2953.

P. 91 par.: Avant l'étude WHI...

AITKEN, J. M., HART, D. M. et LINDSAY, R. « Oestrogen replacement therapy for prevention of osteoporosis after oophorectomy », *British Medical Journal*, vol. 3, 1973, p. 515-518.

GORDAN, G. S., PICCHI, J., ROOF, B. S. « Antifracture efficacy of long-term estrogens for osteoporosis », *Transactions of the Association of American Physicians*, vol. 86, 1973, p. 326-332.

HAMMOND, C. B., JELOVSEK, F. R., LEE, K. L. *et al.* « Effects of long-term estrogen replacement therapy. I. Metabolic effects », *American Journal of Obstetrics and Gynecology*, vol. 133, 1979, p. 525-536.

HUTCHINSON, T. A., POLANSKY, S. M. et FEINSTEIN, A. R. « Post-menopausal oestrogens protect against fractures of hip and distal radius », *Lancet*, 6 oct. 1979, p. 705-709.

SORENSEN, O. H., LUND, B., LUND, B. *et al.* « Effects of 1, alpha vitamin D on bone and muscle in senile osteoporosis », dans McINTYRE, I. et SCELKE, J. (dir.). *Molecular endocrinology*, Amsterdam, Elsevier/North Holland, 1979, p. 309-318.

LINDSAY, R., HART, D.M., FORREST, C. *et al.* « Prevention of spinal osteoporosis in oophorectomised women », *Lancet*, 29 nov. 1980, p. 1151-1153.

STOCK, J. L., CODERRE, J. A., MALLETT, L. E. « Effects of a short course of estrogen on mineral metabolism in postmenopausal women », *Journal of Clinical Endocrinology & Metabolism*, vol. 61, 1985, p. 595-600.

ETTINGER, B., GENANT, H. K. et CANN, C. E. « Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium », *Annals of Internal Medicine*, vol. 106, 1987, p. 40-45.

BARZEL, U. S. « Estrogens in the prevention and treatment of postmenopausal osteoporosis: A review », *The American Journal of Medicine*, vol. 85, 1988, p. 847-850.

MUNK-JENSEN, N., NIELSON, S. P., OBEL, E. B. *et al.* « Reversal of postmenopausal vertebral bone loss by oestrogen and progestogen: A double blind placebo controlled study », *British Medical Journal*, vol. 296, 1988, p. 1150-1152.

The Writing Group for the PEPI trial. « Effects of hormone therapy on bone mineral density. Results from the postmenopausal estrogen/progestin interventions (PEPI) trial », *The Journal of the American Medical Association*, vol. 276, 1996, p. 1389-1396.

RECKER, R. R., DAVIES, K. M., DOWD, R. M. *et al.* « The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women », *Annals of Internal Medicine*, vol. 130, 1999, p. 897-904.

WEISS, S. R., ELLMAN, H., DOLKER, M. *et al.* « A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss », *Obstetrics & Gynecology*, vol. 94, 1999, p. 330-336.

Writing Group for the Women's Health Initiative Investigators. « Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial », *The Journal of the American Medical Association*, vol. 288, 2002, p. 321-333.

ANDERSON, G. L., LIMACHER, M., ASSAF, A. R. *et al.* « Effects of conjugated equine estrogen in post-menopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial », *The Journal of the American Medical Association*, vol. 291, 2004, p. 1701-1712.

par.: *Dans l'étude PEPI...*

The Writing Group for the PEPI trial. « Effects of hormone therapy on bone mineral density. Results from the postmenopausal estrogen/progestin interventions (PEPI) trial », *The Journal of the American Medical Association*, vol. 276, 1996, p. 1389-1396.

par.: *Dans une étude...*

TIRAS, M. B., NOYAN, V., YILDIZ, A. *et al.* « Comparison of different treatment modalities for postmenopausal patients with osteopenia: Hormone replacement therapy, calcitonin and clodronate », *Climacteric*, vol. 3, 2000, p. 92-101.

par.: *De faibles doses...*

DELMAS, P. D., BJARNASON, N. H., MITLAK, B. H. *et al.* « Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women », *The New England Journal of Medicine*, vol. 337, 1997, p. 1641-1647.

WEISS, S. R., ELLMAN, H., DOLKER, M. *et al.* « A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss », *Obstetrics & Gynecology*, vol. 94, 1999, p. 330-336.

par.: *Des études récentes laissent...*

BLACK, D. M., SCHWARTZ, A. V., ENSRUD, K. E. *et al.* « Effects of continuing or stopping alendronate after 5 years of treatment: The fracture intervention trial long-term extension (FLEX): A randomized trial », *The Journal of the American Medical Association*, vol. 296, 2006, p. 2927-2938.

- P. 92 par.: *Récemment, j'ai été...*
BROWN, J. « Étude RUTH: Les deux faces du raloxifène », *Le Médecin du Québec*, vol. 41, 2006, p. 14-17.
tabl.: *Pour en savoir plus...*
GREENSPAN, S. L., BONE, H. G., ETTINGER, M. P. *et al.* « Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: A randomized trial », *Annals of Internal Medicine*, vol. 146, 2007, p. 326-339.
- P. 93 par.: *D'abord, à l'instar...*
AITKEN, J. M., HART, D. M. et LINDSAY, R. « Oestrogen replacement therapy for prevention of osteoporosis after oophorectomy », *British Medical Journal*, vol. 3, 1973, p. 515-518.
par.: *Ensuite, bien que les...*
Revue dans PRIOR, J. C. « Progesterone as a bone-trophic hormone », *Endocrine Reviews*, vol. 11, 1990, p. 386-398.
EASTELL, R. « Treatment of postmenopausal osteoporosis », *The New England Journal of Medicine*, vol. 338, 1998, p. 736-746.
par.: *Selon certains chercheurs, les...*
FELSON, D. T., ZHANG, Y., HANNAN, M. T. *et al.* « The effect of postmenopausal estrogen therapy on bone density in elderly women », *The New England Journal of Medicine*, vol. 329, 1993, p. 1141-1146.
par.: *Dans le squelette, une...*
PARFITT, A. M. « The coupling of bone formation to bone resorption: A critical analysis of the concept and its relevance to the pathogenesis of osteoporosis », *Metabolic Bone Disease & Related Research*, vol. 4, 1982, p. 1-6.
- p. 94 par.: *L'administration d'estrogènes...*
Revue dans PRIOR, J. C. « Progesterone as a bone-trophic hormone », *Endocrine Reviews*, vol. 11, 1990, p. 386-398.
TAYLOR, B. C., SCHREINER, P. J., STONE, K. L. *et al.* « Long-term prediction of incident hip fracture risk in elderly white women: Study of osteoporotic fractures », *Journal of the American Geriatrics Society*, vol. 52, 2004, p. 1479-1486.
par.: *De façon concordante...*
WEISS, S. R., ELLMAN, H., DOLKER, M. *et al.* « A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss », *Obstetrics & Gynecology*, vol. 94, 1999, p. 330-336.
par.: *Actuellement, en médecine, le...*
CHEN, T. L., ARONOW, L. et FELDMAN, D. « Glucocorticoid receptors and inhibition of bone cell growth in primary culture », *Endocrinology*, vol. 100, 1977, p. 619-628.
Revue dans PRIOR, J. C. « Progesterone as a bone-trophic hormone », *Endocrine Reviews*, vol. 11, 1990, p. 386-398.

par.: *De plus en plus...*

PRIOR, J. C. « Progesterone as a bone-trophic hormone », *Endocrine Reviews*, vol. 11, 1990, p. 386-398.

PRIOR, J. C., VIGNA, Y. M., SCHECHTER, M. T. *et al.* « Spinal bone loss and ovulatory disturbances », *The New England Journal of Medicine*, vol. 323, 1990, p. 1221-1227.

TREMOLLIÈRES, F. A., STRONG, D. D., BAYLINK, D. J. *et al.* « Progesterone and promegestone stimulate human bone cell proliferation and insulin-like growth factor-2 production », *Acta Endocrinologica*, vol. 126, 1992, p. 329-337.

SCHMIDT, P. J., NIEMAN, L., DANACEAU, M. A. *et al.* « Estrogen replacement in perimenopause-related depression: A preliminary report », *American Journal of Obstetrics and Gynecology*, vol. 183, 2000, p. 414-420.

par.: *Des chercheurs ont observé...*

NIELSEN, H. K., BRIXEN, K., BOUILLON, R. *et al.* « Changes in biochemical markers of osteoblastic activity during the menstrual cycle », *Journal of Clinical Endocrinology & Metabolism*, vol. 70, 1990, p. 1431-1437.

P. 95 tabl.: *Doit-on prendre des...*

BROWN, J. P., FORTIER, M., FRAME, H. *et al.* « Canadian consensus conference on osteoporosis, 2006 update », *Journal of Obstetrics and Gynaecology Canada*, vol. 28 (suppl. 1), 2006, p. S95-S112.

The North American Menopause Society. « Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society », *Menopause*, vol. 13, 2006, p. 340-367.

GREENSPAN, S. L., BONE, H. G., ETTINGER, M. P. *et al.* « Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: A randomized trial », *Annals of Internal Medicine*, vol. 146, 2007, p. 326-339.

STEFANICK, M. L. « Risk-benefit profiles of raloxifene for women », *The New England Journal of Medicine*, vol. 355, 2006, p. 190-192.

BARRETT-CONNOR, E., MOSCA, L., COLLINS, P. *et al.* « Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women », *The New England Journal of Medicine*, vol. 355, 2006, p. 125-137.

P. 96 par.: *Une étude récente a...*

MARCOVITZ, P. A., TRAN, H. H. et FRANKLIN, B. A. « Usefulness of bone mineral density to predict significant coronary artery disease », *The American Journal of Cardiology*, vol. 96, 2005, p. 1059-1063.

par.: *Des expériences ont montré...*

MANOLAGAS, S. C., JILKA, R. L., HANGOC, G. *et al.* « Increased osteoclast development after estrogen loss: Mediation by interleukin-6 », *Science*, vol. 257, 1992, p. 88-91.

Revue dans JILKA, R. L. « Cytokines, bone remodeling, and estrogen deficiency: A 1998 update », *Bone*, vol. 23, 1998, p. 75-81.

Revue dans MODENA, M. G., BURSI, F., FANTINI, G. *et al.* « Effects of hormone replacement therapy on C-reactive protein levels in healthy postmenopausal women: Comparison between oral and transdermal administration of estrogen », *The American Journal of Medicine*, vol. 113, 2002, p. 331-334.

SUZUKI, S., BROWN, C. M., DELA CRUZ, C. D. *et al.* « Timing of estrogen therapy after ovariectomy dictates the efficacy of its neuroprotective and antiinflammatory actions », *Proceedings of the National Academy of Sciences*, vol. 104, 2007, p. 6013-6018.

P. 99 par. : Selon le Dr Greene...

GREENE, R. A. et FELDON, L. *Perfect Balance*, New York, Clarkson Potter/Publisher, 2005, 351 p.

tabl. : *L'estradiol-17 β et la...*

LAGANIÈRE, J., DEBLOIS G., LEFEBVRE C. *et al.* « Location analysis of estrogen receptor α target promoters reveals that FOXA1 defines a domain of the estrogen response », *Proceedings of the National Academy of Sciences*, vol. 102, 2005, p. 11651-11656.

LEO, J.C.L., WANG, S.M., GUO, C.H. *et al.* « Gene regulation profile reveals consistent anti-cancer properties of progesterone in hormone-independent breast cancer cells transfected with progesterone receptor », *International Journal of Cancer*, vol. 117, 2005, p. 561-568.

P. 100 par. : *En effet, l'estradiol-17 β ...*

MODENA, M. G., MOLINARI, R., MUIA, N. Jr. *et al.* « Double-blind randomized placebo-controlled study of transdermal estrogen replacement therapy on hypertensive postmenopausal women », *American Journal of Hypertension*, vol. 12, 1999, p. 1000-1008.

P. 101 par. : *Chez des hommes transsexuels...*

SLATER, A. J., GUDE, N., CLARKE, I. J. *et al.* « Haemodynamic changes and left ventricular performance during high-dose oestrogen administration to male transsexuals », *British Journal of Obstetrics and Gynaecology*, vol. 93, 1986, p. 532-538.

par. : *Chez les femmes enceintes...*

ELKAYAM, U. « Pregnancy and cardiovascular disease », dans BRAUNWALD, E. (dir.). *Heart Disease*, Philadelphie, W. B. Saunders, 1992, p. 1790-1809.

par. : *Des chercheurs ont observé...*

WEST, S. G., HINDERLITER, A. L., WELLS, E. C. *et al.* « Transdermal estrogen reduces vascular resistance and serum cholesterol in postmenopausal women », *American Journal of Obstetrics and Gynecology*, vol. 184, 2001, p. 926-933.

par. : *L'estradiol-17 β transdermique réduit...*

SEELY, E. W., WALSH, B. W., GERHARD, M. D. *et al.* « Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women », *Hypertension*, vol. 33, 1999, p. 1190-1194.

par. : *En résumé, les estrogènes...*

ALFIE, J., LUGONES, L., BELARDO, A. *et al.* « Hemodynamic effects of transdermal estradiol alone and combined with norethisterone acetate », *Maturitas*, vol. 27, 1997, p. 163-169.

WEST, S. G., HINDERLITER, A. L., WELLS, E. C. *et al.* « Transdermal estrogen reduces vascular resistance and serum cholesterol in postmenopausal women », *American Journal of Obstetrics and Gynecology*, vol. 184, 2001, p. 926-933.

par.: *La progestérone (mais non...*

RYLANCE, P. B., BRINCAT, M., LAFFERTY, K. *et al.* « Natural progesterone and antihypertensive action », *British Medical Journal*, vol. 290, 1985, p. 13-14.

BRALEY, L. M., MENACHERY, A. I., YAO, T. *et al.* « Effect of progesterone on aldosterone secretion in rats », *Endocrinology*, vol. 137, 1996, p. 4773-4778.

par.: *Alors que les estrogènes...*

SITRUK-WARE, R., BRICAIRE, C., DE LIGNIERES, B. *et al.* « Oral micronized progesterone. Bioavailability pharmacokinetics, pharmacological and therapeutic implications. A review », *Contraception*, vol. 36, 1987, p. 373-402.

KUHL, H. « Pharmacokinetics of oestrogens and progestogens », *Maturitas*, vol. 12, 1990, p. 171-197.

P. 102 par.: *À la ménopause...*

CARR, M. C. « The emergence of the metabolic syndrome with menopause », *Journal of Clinical Endocrinology & Metabolism*, vol. 88, 2003, p. 2404-2411.

Revue dans BRUNS, C. M. et KEMNITZ, J. W. « Sex hormones, insulin sensitivity, diabetes mellitus », *ILAR Journal*, vol. 45, 2004, p. 160-169.

par.: *Un taux élevé...*

Revue dans CHIAMVIMONVAT, V. et STERNBERG, L. « Coronary artery disease in women », *Canadian Family Physician*, vol. 44, 1998, p. 2709-2717.

P. 103 par.: *Dans des études épidémiologiques...*

BARRETT-CONNOR, E. et LAAKSO, M. « Ischemic heart disease risk in postmenopausal women. Effects of estrogen use on glucose and insulin levels », *Arteriosclerosis*, vol. 10, 1990, p. 531-534.

NABULSI, A. A., FOLSOM, A. R., WHITE, A. *et al.* « Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women », *The New England Journal of Medicine*, vol. 328, 1993, p. 1069-1075.

Revue dans KARJALAINEN, A., PAASSILTA, M., HEIKKINEN, J. *et al.* « Effects of peroral and transdermal oestrogen replacement therapy on glucose and insulin metabolism », *Clinical Endocrinology*, vol. 54, 2001, p. 165-173.

GODSLAND, I. F., GANGAR, K., WALTON, C. *et al.* « Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy », *Metabolism*, vol. 42, 1993, p. 846-853.

par.: *Ces facteurs agissant par...*

WALTON, C., GODSLAND, I. F., PROUDLER, A. J. *et al.* « The effects of the menopause on insulin sensitivity, secretion and elimination in non-obese, healthy women », *European Journal of Clinical Investigation*, vol. 23, 1993, p. 466-473.

Revue dans KARJALAINEN, A., PAASSILTA, M., HEIKKINEN, J. *et al.* « Effects of peroral and transdermal oestrogen replacement therapy on glucose and insulin metabolism », *Clinical Endocrinology*, vol. 54, 2001, p. 165-173.

BORISSOVA, A.-M., TANKOVA, T., KAMENOVA, P. *et al.* « Effect of hormone replacement therapy on insulin secretion and insulin sensitivity in postmenopausal diabetic women », *Gynecological Endocrinology*, vol. 16, 2002, p. 67-74.

par.: *Chez des femmes ménopausées...*

KARJALAINEN, A., PAASSILTA, M., HEIKKINEN, J. *et al.* « Effects of peroral and transdermal oestrogen replacement therapy on glucose and insulin metabolism », *Clinical Endocrinology*, vol. 54, 2001, p. 165-173.

par.: *L'estradiol-17 β augmenterait à...*

CAGNACCI, A., SOLDANI, R., CARRIERO, P. L. *et al.* « Effects of low doses of transdermal 17 beta-estradiol on carbohydrate metabolism in postmenopausal women », *Journal of Clinical Endocrinology & Metabolism*, vol. 74, 1992, p. 1396-1400.

CAGNACCI, A., TUVERI, F., CIRILLO, R. *et al.* « The effect of transdermal 17- β -estradiol on glucose metabolism of postmenopausal women is evident during the oral but not the intravenous glucose administration », *Maturitas*, vol. 28, 1997, p. 163-167.

par.: *Cet effet n'est...*

NADAL, A., ROVIRA, J. M., LARIBI, O. *et al.* « Rapid insulinotropic effect of 17 β -estradiol via a plasma membrane receptor », *The Journal of the Federation of American Societies for Experimental Biology*, vol. 12, 1998, p. 1341-1348.

P. 104 par.: *Chez des souris servant...*

EFRAT, S. « Sexual dimorphism of pancreatic β -cell degeneration in transgenic mice expressing an insulin-ras hybrid gene », *Endocrinology*, vol. 128, 1991, p. 897-901.

par.: *Dans une autre étude...*

KUZNETSOVA, V. A. et GARUSOVA, E. V. « Clinical significance of glycolysis indicators in the evaluation of the condition of the foetus and new-born infant », *Pediatrics*, vol. 10, 1990, p. 12-16.

P. 105 par.: *La progestérone aurait des...*

LANDAU, R. L. et LUGIBIHL, K. « The catabolic and natriuretic effects of progesterone in man », *Recent Progress in Hormone Research*, vol. 17, 1961, p. 249-281.

par.: *Un taux adéquat...*

GREENE, R. A. et FELDON, L. *Perfect Balance*, New York, Clarkson Potter/Publisher, 2005, 351 p.

par.: *La progestérone contribue à...*

FRIESS, E., TAGAYA, H., TRACHSEL, L. *et al.* « Progesterone-induced changes in sleep in male subjects », *American Journal of Physiology*, vol. 272, 1997, p. E885-E891.

P. 107 par.: *Une étude randomisée...*

MODENA, M. G., MOLINARI, R., MUIA, N. Jr *et al.* « Double-blind randomized placebo-controlled study of transdermal estrogen replacement therapy on hypertensive postmenopausal women », *American Journal of Hypertension*, vol. 12, 1999, p. 1000-1008.

P. 113 tabl.: *Hormonothérapie bioéquivalente*

LEVINE, H. et WATSON, N. « Comparison of the pharmacokinetics of Crinone 8% administered vaginally versus Prometrium administered orally in postmenopausal women », *Fertility and Sterility*, vol. 73, 2000, p. 516-521.

- P. 116 par.: *Certains diront que le...*
Revue dans FREEDMAN, O. C., VERMA, S. et CLEMONS, M. J. « Pre-menopausal breast cancer and aromatase inhibitors: Treating a new generation of women », *Breast Cancer Research and Treatment*, vol. 99, 2006, p. 241-247.
- P. 119 par.: *Une étude du Collaborative...*
Collaborative Group on Hormonal Factors in Breast Cancer. « Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer », *Lancet*, vol. 350, 1997, p. 1047-1059.
par.: *Dans une étude publiée...*
MARCHBANKS, P. A., McDONALD, J. A., WILSON, H. G. *et al.* « Oral contraceptives and the risk of breast cancer », *The New England Journal of Medicine*, vol. 346, 2002, p. 2025-2032.
- P. 120 tabl.: *Ainsi...*
MARCHBANKS, P. A., McDONALD, J. A., WILSON, H. G. *et al.* « Oral contraceptives and the risk of breast cancer », *The New England Journal of Medicine*, vol. 346, 2002, p. 2025-2032.
- P. 121 par.: *Deux études basées sur...*
COLDITZ, G. A., HANKINSON, S. E., HUNTER, D. J. *et al.* « The use of estrogens and progestins and the risk of breast cancer in postmenopausal women », *The New England Journal of Medicine*, vol. 332, 1995, p. 1589-1593.
Million Women Study Collaborators. « Breast cancer and hormone-replacement therapy in the Million Women study », *Lancet*, vol. 362, 2003, p. 419-427.
tabl.: *Ces deux études présentent...*
Million Women Study Collaborators. « Breast cancer and hormone-replacement therapy in the Million Women study », *Lancet*, vol. 362, 2003, p. 419-427.
ROZENBAUM, H. « Cancer du sein et hormonothérapie substitutive dans l'étude the Million Women Study », (analyse de l'article: « Breast cancer and hormone-replacement therapy in the Million Women study », *Lancet*, vol. 362, 2003, p. 419-427.) <http://www.menopauseafem.com/medical/analyse2.php3?id=493>
par.: *Ces failles peuvent être...*
CHEN, W.Y. *et al.* « Long-term estrogen therapy linked to increased breast cancer risk », *Archives of Internal Medicine*, vol. 166, 2006, p. 1027-1032.
- P. 122 par.: *Des chercheurs faisant partie...*
Collaborative Group on Hormonal Factors in Breast Cancer. « Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer », *Lancet*, vol. 350, 1997, p. 1047-1059.
par.: *Ce qui m'a particulièrement...*
BÉLISLE, S. et DERZKO, C. « Hormonothérapie substitutive et cancer. Consensus canadien sur la ménopause et l'ostéoporose », dans ROWE, T. (dir.), « Directives cliniques de la SOGC », *Journal of Obstetrics and Gynaecology Canada*, vol. 23, 2001, p. 1226-1230.

par.: *L'étude Breast Cancer Demonstration...*

SCHAIRER, C., LUBIN, J., TROISI, R. *et al.* « Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk », *The Journal of the American Medical Association*, vol. 283, 2000, p. 485-491.

P. 123 par.: *Ces chercheurs n'ont...*

LI, C. I., MALONE, K. E., PORTER, P. L. *et al.* « Relationship between long durations and different regimens of hormone therapy and risk of breast cancer », *The Journal of the American Medical Association*, vol. 289, 2003, p. 3254-3263.

par.: *Des chercheurs ont comparé...*

SHAH, N. R., BORENSTEIN, J., DUBOIS, R.W. *et al.* « Postmenopausal hormone therapy and breast cancer: A systematic review and meta-analysis », *The Journal of The North American Menopause Society*, vol. 12, 2005, p. 668-678.

P. 124 par.: *Une analyse de toutes...*

COLLINS, J. A., BLAKE, J. M. et CROSIGNANI, P. G. « Breast cancer risk with postmenopausal hormonal treatment », *Human Reproduction Update*, vol. 11, 2005, p. 545-560.

par.: *Une étude de la...*

LYYTINEN, H., PUKKALA, E. et YLIKORKALA, O. « Breast cancer risk in postmenopausal women using estrogen-only therapy », *Obstetrics & Gynecology*, vol. 108, 2006, p. 1354-1360.

par.: *En avril 2006, le...*

STEFANICK, M.L., ANDERSON, G.L., MARGOLIS, K.L. *et al.* « Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy », *The Journal of the American Medical Association*, vol. 295, 2006, p. 1647-1657.

P. 125 tabl.: *Pour en savoir plus...*

PERSSON, I., THURFJELL, E., BERGSTRÖM, R. *et al.* « Hormone replacement therapy and the risk of breast cancer. Nested case-control study in a cohort of Swedish women attending mammography screening », *International Journal of Cancer*, vol. 72, 1997, p. 758-761.

par.: *L'étude MISSION est une...*

ESPIÉ, M., MARES, P., DE REILHAC, P. *et al.* « Breast cancer in postmenopausal women with and without hormone replacement therapy: Preliminary results of the MISSION study », *Gynecological Endocrinology*, vol. 22, 2006, p. 423-431.

P. 127 par.: *Il est généralement admis...*

BULBROOK, R. D., SWAIN, M. C., WANG, D. Y. *et al.* « Breast cancer in Britain and Japan: Plasma oestradiol-17 β , oestrone and progesterone, and their urinary metabolites in normal British and Japanese women », *European Journal of Cancer*, vol. 12, 1976, p. 725-735.

par.: *De 1961 à 1976...*

BULBROOK, R. D., MOORE, J. W., CLARK, G. M. G. *et al.* « Plasma oestradiol and progesterone levels in women with varying degrees of risk of breast cancer », *European Journal of Cancer*, vol. 14, 1978, p. 1369-1375.

P. 128 par.: *Il y a plus...*

SHERMAN, B. M. et KORENMAN, S. G. « Inadequate corpus luteum function: A pathophysiological interpretation of human breast cancer epidemiology », *Cancer*, vol. 33, 1974, p. 1306-1312.

- par.: *Déjà en 1964, un...*
- GRATTAROLA, R. « The premenstrual endometrial pattern of women with breast cancer », *Cancer*, vol. 17, 1964, p. 1119-1122.
- P. 129 par.: *En effet, chez les...*
- COWAN, L. D., GORDIS, L., TONASCIA, J. A. *et al.* « Breast cancer incidence in women with a history of progesterone deficiency », *American Journal of Epidemiology*, vol. 114, 1981, p. 209-217.
- par.: *Des chercheurs ont observé...*
- SITRUK-WARE, L. R., STERKERS, N., MOWSZOWICZ, I. *et al.* « Inadequate corpus luteal function in women with benign breast diseases », *Journal of Clinical Endocrinology & Metabolism*, vol. 44, 1977, p. 771-774.
- par.: *Actuellement, on sait que...*
- HARTMANN, L. C., SELLERS, T. A., FROST, M. H. *et al.* « Benign breast disease and the risk of breast cancer », *The New England Journal of Medicine*, vol. 353, 2005, p. 229-237.
- P. 130 par.: *Dans une étude, les...*
- WYSOWSKI, D. K., COMSTOCK, G. W., HELSING, K. J. *et al.* « Sex hormone levels in serum in relation to the development of breast cancer », *American Journal of Epidemiology*, vol. 125, 1987, p. 791-799.
- BEATTIE, M. S., COSTANTINO, J. P., CUMMINGS, S. R. *et al.* « Endogenous sex hormones, breast cancer risk, and tamoxifen response: An ancillary study in the NSABP breast cancer prevention trial (P-1) », *Journal of the National Cancer Institute*, vol. 98, 2006, p. 110-115.
- P. 131 tabl.: *Estradiol*
- Laboratoire Roche, 1999 (test Estradiol Elecsys)
- P. 137 par.: *Évidemment, plus il...*
- KOSHLAND, D. E. J.-R. « Molecule of the year: The DNA repair enzyme », *Science*, vol. 266, 1994, p. 1925.
- STRACHAN, T. et READ, A. P. *Génétique moléculaire humaine*, Flammarion Médecine-Sciences, 1998, 597 p.
- par.: *Les mutations peuvent aussi...*
- GOODMAN Y., BRUCE A.J., CHENG B. *et al.* « Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons », *Journal of Neurochemistry*, vol. 66, 1996, p. 1836-1844.
- ROOF, R.L., HOFFMAN, S.W., STEIN, D.G. « Progesterone protects against lipid peroxidation following traumatic brain injury in rats », *Molecular and Chemical Neuropathology*, vol. 31, 1997, p. 1-11.
- GREENE R.A. et FELDON L. *Perfect Balance*, New York, Clarkson Potter/Publisher, 2005, 351p.
- P. 138 par.: *Toutes nos cellules ont...*
- RUST, C. et GORES, G. J. « Apoptosis and liver disease », *The American Journal of Medicine*, vol. 108, 2000, p. 567-574.

- P. 139 par.: *Chez les femmes porteuses...*
 FORD, D., EASTON, D. F., BISHOP, D. T. *et al.* « Risks of cancer in BRCA1-mutation carriers », *Lancet*, vol. 343, 1994, p. 692-695.
 par.: *Actuellement, il semble que...*
 FOULKES, W. D. et NAROD, S. A. « Hereditary breast and ovarian cancer: Epidemiology, genetics, screening and predictive testing », *Clinical and Investigative Medicine. Médecine Clinique et Expérimentale*, vol. 18, 1995, p. 473-483.
- P. 140 par.: *Dans les cancers, les...*
 BARTEK, J., BARTKOVA, J., VOJTESEK, B. *et al.* « Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro », *International Journal of Cancer*, vol. 46, 1990, p. 839-844.
 LEVINE, A. J. « p53, the cellular gatekeeper for growth and division », *Cell*, vol. 88, 1997, p. 323-331.
 par.: *Vours verrez, au cours...*
 GOODMAN, Y., BRUCE, A. J., CHENG, B. *et al.* « Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons », *Journal of Neurochemistry*, vol. 66, 1996, p. 1836-1844.
 ROOF, R. L., HOFFMAN, S. W. et STEIN, D. G. « Progesterone protects against lipid peroxidation following traumatic brain injury in rats », *Molecular and Chemical Neuropathology*, vol. 31, 1997, p. 1-11.
 GREENE R. A. et FELDON L. *Perfect Balance*, New York, Clarkson Potter/Publisher, 2005, 351p.
- P. 142 par.: *Quatre types d'enzymes...*
 POUTANEN, M., ISOMAA, V., PELTOKETO, H. *et al.* « Role of 17 β -hydroxysteroid dehydrogenase type 1 in endocrine and intracrine estradiol biosynthesis », *The Journal of Steroid Biochemistry and Molecular Biology*, vol. 55, 1995, p. 525-532.
 GHERSEVICH S.A., POUTANEN M.H., MARTIKAINEN H.K. *et al.* « Expression of 17 β -hydroxysteroid dehydrogenase in human granulosa cells: Correlation with follicular size, cytochrome P450 aromatase activity and oestradiol production », *Journal of Endocrinology*, vol. 143, 1994, p. 139-150.
 par.: *La HSD-17 β types 1 et 2...*
 CASEY, M. L., MACDONALD, P. C. et ANDERSSON, S. « 17 β -Hydroxysteroid dehydrogenase type 2: Chromosomal assignment and progestin regulation of gene expression in human endometrium », *Journal of Clinical Investigation*, vol. 94, 1994, p. 2135-2141.
 GURPIDE, E. « Enzymatic modulation of hormonal action at the target tissue », *Journal of Toxicology and Environmental Health*, vol. 4, 1978, p. 249-268.
 par.: *L'enzyme aromatase est...*
 Revue dans GRUBER, C. J., TSCHUGGUEL, W., SCHNEEBERGER, C. *et al.* « Production and actions of estrogens », *The New England Journal of Medicine*, vol. 346, 2002, p. 340-352.
- P. 144 tabl.: *Anastasia (1^{er} tableau)*
 YUE, W., SANTEN, R. J., WANG, J. P. *et al.* « Aromatase within the breast », *Endocrine-Related Cancer*, vol. 6, 1999, p. 157-164.

tabl.: Anastasia (2^e tableau)

EDERY, M., GOUSSARD, J., DEHENNIN, L. *et al.* « Endogenous oestradiol-17 β concentration in breast tumours determined by mass fragmentography and radioimmunoassay: Relationship to receptor content », *European Journal of Cancer*, vol. 17, 1981, p. 115-120.

VAN LANDEGHEM, A. A. J., POORTMAN, J., NABUURS, M. *et al.* « Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue », *Cancer Research*, vol. 45, 1985, p. 2900-2906.

YUE, W., SANTEN, R. J., WANG, J. P. *et al.* « Aromatase within the breast », *Endocrine-Related Cancer*, vol. 6, 1999, p. 157-164.

P. 145 par.: *Les chercheurs ont observé...*

YUE, W., SANTEN, R. J., WANG, J. P. *et al.* « Aromatase within the breast », *Endocrine-Related Cancer*, vol. 6, 1999, p. 157-164.

P. 147 par.: *La plupart des tissus...*

ERIKSEN E.F., COLVARD D.S., BERG N.J. *et al.* « Evidence of estrogen receptors in normal human osteoblast-like cells » *Science*, vol. 241, 1988, p. 84-86.

INGEGNO, M. D., MONEY, S. R., THELMO, W. *et al.* « Progesterone receptors in the human heart and great vessels », *Laboratory Investigation*, vol. 59, 1988, p. 353-356.

DOGLIONI, C., GAMBACORTA, M., ZAMBONI, G. *et al.* « Immunocytochemical localization of progesterone receptors in endocrine cells of the human pancreas », *American Journal of Pathology*, vol. 137, 1990, p. 999-1005.

BONACCI, R., PINCHERA, A., FIERABRACCI, P. *et al.* « Relevance of estrogen and progesterone receptors enzyme immunoassay in malignant, benign and surrounding normal thyroid tissue », *Journal of Endocrinological Investigation*, vol. 19, 1996, p. 159-164.

WANG, H., CRITCHLEY, H. O. D., KELLY, R. W. *et al.* « Progesterone receptor subtype B is differentially regulated in human endometrial stroma », *Molecular Human Reproduction*, vol. 4, 1988, p. 407-412.

MULAC-JERICEVIC, B., MULLINAX, R. A., DEMAYO, F. J. *et al.* « Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform », *Science*, vol. 289, 2000, p. 1751-1754.

par.: *En effet, un taux...*

HORWITZ, K. B., MOCKUS, M. B., PIKE, A. W. *et al.* « Progesterone receptor replenishment in T47D human breast cancer cells. Roles of protein synthesis and hormone metabolism », *Journal of Biological Chemistry*, vol. 258, 1983, p. 7603-7610.

REE, A. H., LANDMARK, B. F., ESKILD, W. *et al.* « Autologous down-regulation of messenger ribonucleic acid and protein levels for estrogen receptors in MCF-7 cells: An inverse correlation to progesterone receptor levels », *Endocrinology*, vol. 124, 1989, p. 2577-2583.

CLARKE, R. B., HOWELL, A. et ANDERSON, E. « Estrogen sensitivity of normal human breast tissue in vivo and implanted into athymic nude mice: Analysis of the relationship between estrogen-induced proliferation and progesterone receptor expression », *Breast Cancer Research and Treatment*, vol. 45, 1997, p. 121-133.

TURGEON, J. L. et WARING, D. W. « Progesterone regulation of the progesterone receptor in rat gonadotropes », *Endocrinology*, vol. 141, 2000, p. 3422-3429.

par.: *Un taux élevé de...*

TURGEON, J. L. et WARING, D. W. « Progesterone regulation of the progesterone receptor in rat gonadotropes », *Endocrinology*, vol. 141, 2000, p. 3422-3429.

HSUEH A.J.W., PECK E.J. J.-R., CLARK J.H. « Progesterone antagonism of the oestrogen receptor and oestrogen-induced uterine growth », *Nature*, vol. 254, 1975, p. 337-339.

P. 148 tabl.: *Pour en savoir plus...*

VEGETO, E., SHAHBAZ, M. M., WEN, D. X. *et al.* « Human progesterone receptor A form is a cell-and promoter-specific repressor of human progesterone receptor B function », *Molecular Endocrinology*, vol. 7, 1993, p. 1244-1255.

McDONNELL, D. P. et GOLDMAN, M. E. « RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism », *Journal of Biological Chemistry*, vol. 269, 1994, p. 11945-11949.

McDONNELL, D. P., SHAHBAZ, M. M., VEGETO, E. *et al.* « The human progesterone receptor A-form functions as a transcriptional modulator of mineralocorticoid receptor transcriptional activity », *The Journal of Steroid Biochemistry and Molecular Biology*, vol. 48, 1994, p. 425-432.

MULAC-JERICEVIC, B., MULLINAX, R. A., DEMAYO, F. J. *et al.* « Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform », *Science*, vol. 289, 2000, p. 1751-1754.

Revue dans INOUE, T., AKAHIRA, J.-I., TAKEYAMA, J. *et al.* « Spatial and topological distribution of progesterone receptor A and B isoforms during human development », *Molecular and Cellular Endocrinology*, vol. 182, 2001, p. 83-89.

INOUE, T., AKAHIRA, J.-I., SUZUKI, T. *et al.* « Progesterone production and actions in the human central nervous system and neurogenic tumors », *Journal of Clinical Endocrinology & Metabolism*, vol. 87, 2002, p. 5325-5331.

P. 150 par.: *Des chercheurs ont vérifié...*

POTTEN, C. S., WATSON, R. J., WILLIAMS, G. T. *et al.* « The effect of age and menstrual cycle upon proliferative activity of the normal human breast », *British Journal of Cancer*, vol. 58, 1988, p. 163-170.

par.: *Des études ont montré...*

MEYER, J. S. et CONNOR, R. E. « Cell proliferation in fibrocystic disease and postmenopausal breast ducts measured by thymidine labeling », *Cancer*, vol. 50, 1982, p. 746-751.

WALKER, K. J., PRICE-THOMAS, J. M., CANDLISH, W. *et al.* « Influence of the antioestrogen tamoxifen on normal breast tissue », *British Journal of Cancer*, vol. 64, 1991, p. 764-768.

POTTEN, C. S., WATSON, R. J., WILLIAMS, G. T. *et al.* « The effect of age and menstrual cycle upon proliferative activity of the normal human breast », *British Journal of Cancer*, vol. 58, 1988, p. 163-170.

P. 151 par.: *Des études ont aussi...*

POTTEN, C. S., WATSON, R. J., WILLIAMS, G. T. *et al.* « The effect of age and menstrual cycle upon proliferative activity of the normal human breast », *British Journal of Cancer*, vol. 58, 1988, p. 163-170.

par.: *L'utilisation de contraceptifs...*

ANDERSON, T. J., BATTERSBY, S., KING, R. J. B. *et al.* « Oral contraceptive use influences resting breast proliferation », *Human Pathology*, vol. 20, 1989, p. 1139-1144.

WILLIAMS, G., ANDERSON, E., HOWELL, A. *et al.* « Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast », *International Journal of Cancer*, vol. 48, 1991, p. 206-210.

HARGREAVES, D. F., KNOX, F., SWINDELL, R. *et al.* « Epithelial proliferation and hormone receptor status in the normal post-menopausal breast and the effects of hormone replacement therapy », *British Journal of Cancer*, vol. 78, 1998, p. 945-949.

P. 152 par.: *Des chercheurs ont trouvé...*

LIDLAW, I. J., CLARKE, R. B., HOWELL, A. *et al.* « The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone », *Endocrinology*, vol. 136, 1995, p. 164-171.

par.: *Étonnamment, en 1962, un...*

KENNEDY, B. J. « Massive estrogen administration in premenopausal women with metastatic breast cancer », *Cancer*, vol. 15, 1962, p. 641-648.

P. 153 par.: *Plusieurs chercheurs ont observé...*

CLARKE, R. B., HOWELL, A. et ANDERSON, E. « Estrogen sensitivity of normal human breast tissue in vivo and implanted into athymic nude mice: Analysis of the relationship between estrogen-induced proliferation and progesterone receptor expression », *Breast Cancer Research and Treatment*, vol. 45, 1997, p. 121-133.

POTTEN, C. S., WATSON, R. J., WILLIAMS, G. T. *et al.* « The effect of age and menstrual cycle upon proliferative activity of the normal human breast », *British Journal of Cancer*, vol. 58, 1988, p. 163-170.

par.: *Une étude d'immunohistochimie...*

SÖDERQVIST, G., ISAKSSON, E., VON SCHOULTZ, B. *et al.* « Proliferation of breast epithelial cells in healthy women during the menstrual cycle », *American Journal of Obstetrics and Gynecology*, vol. 176, 1997, p. 123-128.

par.: *Comme la prolifération est...*

MASTERS, J. R. W., DRIFE, J. O. et SCARISBRICK, J. J. « Cyclic variation of DNA synthesis in human breast epithelium », *Journal of the National Cancer Institute*, vol. 58, 1977, p. 1263-1265.

POTTEN, C. S., WATSON, R. J., WILLIAMS, G. T. *et al.* « The effect of age and menstrual cycle upon proliferative activity of the normal human breast », *British Journal of Cancer*, vol. 58, 1988, p. 163-170.

SÖDERQVIST, G., ISAKSSON, E., VON SCHOULTZ, B. *et al.* « Proliferation of breast epithelial cells in healthy women during the menstrual cycle », *American Journal of Obstetrics and Gynecology*, vol. 176, 1997, p. 123-128.

par.: *Dans le but de...*

LIDLAW, I. J., CLARKE, R. B., HOWELL, A. *et al.* « The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone », *Endocrinology*, vol. 136, 1995, p. 164-171.

- P. 154 par.: *En effet, la production...*
Revue dans GRUBER, C. J., TSCHUGGUEL, W., SCHNEEBERGER, C. *et al.* « Production and actions of estrogens », *The New England Journal of Medicine*, vol. 346, 2002, p. 340-352.
par.: *Les chercheurs ont observé...*
McMANUS, M. J. et WELSCH, C. W. « The effect of estrogen, progesterone, thyroxine and human placental lactogen on DNA synthesis of human breast ductal epithelium maintained in athymic nude mice », *Cancer*, vol. 54, 1984, p. 1920-1927.
par.: *L'étude dont nous...*
LAIDLAW, I. J., CLARKE, R. B., HOWELL, A. *et al.* « The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone », *Endocrinology*, vol. 136, 1995, p. 164-171.
par.: *Cependant, d'autres chercheurs...*
CHANG, K.-J., LEE, T. T. Y., LINARES-CRUZ, G. *et al.* « Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo », *Fertility and Sterility*, vol. 63, 1995, p. 785-791.
- P. 155 par.: *Des chercheurs ont repris...*
FOIDART, J.-M., COLIN, C., DENOO, X. *et al.* « Estradiol and progesterone regulate the proliferation of human breast epithelial cells », *Fertility and Sterility*, vol. 69, 1998, p. 963-969.
- P. 158 par.: *J'ai été étonnée...*
CURTIS, S. W., WASHBURN, T., SEWALL, C. *et al.* « Physiological coupling of growth factor and steroid receptor signaling pathways: Estrogen receptor knockout mice lack estrogen-like response to epidermal growth factor », *Proceedings of the National Academy of Sciences of the United States of America*, vol. 93, 1996, p. 12626-12630.
- P. 159 par.: *Des données épidémiologiques montrent...*
HUTCHINS, G. G. « Estradiol and insulin crosstalk in breast cancer », communication dans *DigitalCommons@The Texas Medical Center*, 2001.
par.: *De façon concordante, une...*
KENT, A. « Obesity, death and breast cancer », *BJOG An International Journal of Obstetrics and Gynaecology*, vol. 113, 2006, p. 1222-1223.
par.: *L'explication actuellement répandue...*
Endogenous Hormones and Breast Cancer Collaborative Group. « Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women », *Journal of the National Cancer Institute*, vol. 95, 2003, p. 1218-1226.
- P. 160 par.: *Une étude d'envergure...*
TRETTLI, S. « Height and weight in relation to breast cancer morbidity and mortality. A prospective study of 570.000 women in Norway », *International Journal of Cancer*, vol. 44, 1989, p. 23-30.
- P. 161 tabl.: *Pour en savoir plus...*
VAN DER BURG, B., RUTTERMAN, G. R., BLANKENSTEIN, M. A. *et al.* « Mitogenic stimulation of human breast cancer cells in a growth factor defined medium: Synergistic action of insulin and estrogen », *Journal of Cellular Physiology*, vol. 123, 1988, p. 101-108.

- NEWTON, C. J., BURIC, R., TRAPP, T. *et al.* « The unliganded estrogen receptor (ER) transduces growth factor signals », *The Journal of Steroid Biochemistry and Molecular Biology*, vol. 48, 1994, p. 481-486.
- P. 163 par.: *Une étude suédoise impliquant...*
- STATTIN, P., BJÖR, O., FERRARI, P. *et al.* « Prospective study of hyperglycemia and cancer risk », *Diabetes Care*, vol. 30, 2007, p. 561-567.
- par.: *Une étude réalisée par...*
- COURNOT M., MARQUIÉ J.-C., ANSIAU D. *et al.* « Relation between body mass index and cognitive function in healthy middle-aged men and women », *Neurology*, vol. 67, 2006, p. 1208-1214.
- par.: *L'exercice physique pratiqué...*
- McTIERNAN, A., ULRICH, C., SLATE, S. *et al.* « Physical activity and cancer etiology: Associations and mechanisms », *Cancer Causes Control*, vol. 9, 1998, p. 487-509.
- P. 164 par.: *Pour en savoir plus...*
- McMICHAEL-PHILIPPS, D. F., HARDING, C., MORTON, M. *et al.* « The effects of soy supplementation on epithelial proliferation in the normal breast », *Breast Cancer Research and Treatment*, vol. 41, 1996, p. 263.
- par.: *D'abord, les chercheurs...*
- BULBROOK, R. D., SWAIN, M. C., WANG, D. Y. *et al.* « Breast cancer in Britain and Japan: Plasma oestradiol-17 β , oestrone and progesterone, and their urinary metabolites in normal British and Japanese women », *European Journal of Cancer*, vol. 12, 1976, p. 725-735.
- par.: *De plus, la plus...*
- Revue dans BULBROOK, R. D., SWAIN, M. C., WANG, D. Y. *et al.* « Breast cancer in Britain and Japan: Plasma oestradiol-17 β , oestrone and progesterone, and their urinary metabolites in normal British and Japanese women », *European Journal of Cancer*, vol. 12, 1976, p. 725-735.
- P. 168 par.: *À mon sens, un...*
- ROCA, C. A., SCHMIDT, P. J., ALTEMUS M. *et al.* « Differential menstrual cycle regulation of hypothalamic-pituitary-adrenal axis in women with premenstrual syndrome and controls », *Journal of Clinical Endocrinology & Metabolism*, vol. 88, 2003, p. 3057-3063.
- P. 169 par.: *Étant donné les répercussions...*
- PORTER, J.-C. « Hormonal regulation of breast development and activity », *The Journal of Investigative Dermatology*, vol. 63, 1974, p. 85-92.
- P. 171 par.: *Lorsqu'on découvre...*
- Revue dans ALTUNDAG, K. et IBRAHIM, N. K. « Aromatase inhibitors in breast cancer: An overview », *The Oncologist*, vol. 11, 2006, p. 553-562.
- P. 172 par.: *Dans la Million Women...*
- Million Women Study Collaborators. « Breast cancer and hormone-replacement therapy in the Million Women study », *Lancet*, vol. 362, 2003, p. 419-427.
- ROZENBAUM, H. « Cancer du sein et hormonothérapie substitutive dans l'étude the Million Women Study », (analyse de l'article: « Breast cancer and hormone-replacement therapy in the Million Women study », *Lancet*, vol. 362, 2003, p. 419-427.) <http://www.menopauseafem.com/medical/analyse2.php3?id=493>

par.: *Une étude a effectivement...*

Revue dans NATRAJAN, P.K., SOUMAKIS, K., GAMBRELL, J.-R. R.D. « Estrogen replacement therapy in women with previous breast cancer », *American Journal of Obstetrics and Gynecology*, vol. 181, 1999, p. 288-295.

P. 173 par.: *Saviez-vous que...*

WREN, B. G. « Hormonal replacement therapy and breast cancer », *European Menopause Journal*, vol. 2, 1995, p. 13-19.

P. 174 par.: *Les femmes ayant un...*

LEWIS, S., LOCKER, A., TODD, J.H. *et al.* « Expression of epidermal growth factor receptor in breast carcinoma », *Journal of Clinical Pathology*, vol. 43, 1990, p. 385-389.

tabl.: *Saviez-vous que...*

WREN, B. G. « Hormonal replacement therapy and breast cancer », *European Menopause Journal*, vol. 2, 1995, p. 13-19.

P. 176 par.: *Chez les femmes ménopausées...*

ALTUNDAG, K. et IBRAHIM, N. K. « Aromatase inhibitors in breast cancer: An overview », *The Oncologist*, vol. 11, 2006, p. 553-562.

par.: *Le tamoxifène entraînerait une...*

FISHER, B., COSTANTINO, J. P., WICKERHAM, D. L. *et al.* « Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study », *Journal of the National Cancer Institute*, vol. 97, 2005, p. 1652-1662.

TSAO, A. S., KIM, E. S. et HONG, W. K. « Chemoprevention of cancer », *CA: A Cancer Journal for Clinicians*, vol. 54, 2004, p. 150-180.

Revue dans ALTUNDAG, K. et IBRAHIM, N. K. « Aromatase inhibitors in breast cancer: An overview », *The Oncologist*, vol. 11, 2006, p. 553-562.

P. 177 par.: *Les effets négatifs du...*

CUZICK, J., POWLES, T., VERONESI, U. *et al.* « Overview of the main outcomes in breast-cancer prevention trials », *Lancet*, vol. 361, 2003, p. 296-300.

MCCARTHY N. Better breast CA survival gives MDs new challenges. Rapporté par BITOMSKY M. dans *The Medical Post*, 24 janvier 2006, p. 38.

par.: *Entre autres à cause...*

FISHER, B., COSTANTINO, J. P., WICKERHAM, D. L. *et al.* « Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study », *Journal of the National Cancer Institute*, vol. 90, 1998, p. 1371-1388.

POWLES, T., EELES, R., ASHLEY S. *et al.* « Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial », *Lancet*, vol. 352, 1998, p. 98-101.

par.: *Chez les femmes ménopausées...*

ALTUNDAG, K. et IBRAHIM, N. K. « Aromatase inhibitors in breast cancer: An overview », *The Oncologist*, vol. 11, 2006, p. 553-562.

The Writing Committee. « A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer », *The New England Journal of Medicine*, vol. 353, 2006, p. 2747-2757.

par.: *Des stratégies utilisant le...*

COOMBES, R. C., HALL, E., GIBSON, L.J. *et al.* « A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer », *The New England Journal of Medicine*, vol. 350, 2004, p. 1081-1092.

Revue dans ALTUNDAG, K. et IBRAHIM, N. K. « Aromatase inhibitors in breast cancer: An overview », *The Oncologist*, vol. 11, 2006, p. 553-562.

P. 178 par.: *Nous avons vu que...*

MILLER, W. R. et O'NEILL, J. « The importance of local synthesis of estrogen within the breast », *Steroids*, vol. 50, 1987, p. 537-548.

P. 179 par.: *Des études ont montré...*

LONNING, P. E. « Pharmacology of new aromatase inhibitors », *Breast*, vol. 5, 1996, p. 202-208.

GEISLER, J., KING, N., ANKER, G. *et al.* « In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients », *Clinical Cancer Research*, vol. 4, 1998, p. 2089-2093.

P. 180 par.: *Des chercheurs ont déjà...*

MILLER, W. R. et O'NEILL, J. « The importance of local synthesis of estrogen within the breast », *Steroids*, vol. 50, 1987, p. 537-548.

P. 181 par.: *La privation en estradiol...*

YUE, W., SANTEN, R. J., WANG, J. P. *et al.* « Aromatase within the breast », *Endocrine-Related Cancer*, vol. 6, 1999, p. 157-164.

MASAMURA, S., SANTNER, S. J., HEITJAN, D. F. *et al.* « Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells », *Journal of Clinical Endocrinology & Metabolism*, vol. 80, 1995, p. 2918-2925.

SANTEN, R. J., SONG, R. X., ZHANG, Z. *et al.* « Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity », *Endocrine-Related Cancer*, vol. 12 (suppl. 1), 2005, p. S61-S73.

par.: *D'autres chercheurs ont...*

POLLOW, K., BOQUOI, E., BAUMANN, J. *et al.* « Comparison of the in vitro conversion of estradiol-17 β to estrone of normal and neoplastic human breast tissue », *Molecular and Cellular Endocrinology*, vol. 6, 1977, p. 333-348.

MEHTA R.R., VALCOURT L., GRAVES J. *et al.* « Subcellular concentrations of estrone, estradiol, androstenedione and 17 β -hydroxysteroid dehydrogenase (17- β -OH-SDH) activity in malignant and non-malignant human breast tissues », *International Journal of Cancer*, vol. 40, 1987, p. 305-308.

P. 183 par.: *Une étude a montré...*

POWLES, T. J. « Tamoxifen and oestrogen replacement », *Lancet*, vol. 336, 1990, p. 48.

VERONESI, U., MAISONNEUVE, P., COSTA, A. *et al.* « Prevention of breast cancer with Tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women », *Lancet*, vol. 352, 1998, p. 93-97.

P. 185 par.: *À l'instar de...*

ARPINO, G., WEISS, H., LEE, A. V. *et al.* « Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance », *Journal of the National Cancer Institute*, vol. 97, 2005, p. 1254-1261.

par.: *Des recherches montrent que...*

WALKER, K. J., PRICE-THOMAS, J. M., CANDLISH, W. *et al.* « Influence of the antioestrogen tamoxifen on normal breast tissue », *British Journal of Cancer*, vol. 64, 1991, p. 764-768.

HORWITZ, K. B., KOSEKI, Y. et MCGUIRE, W. L. « Estrogen control of progesterone receptor in human breast cancer: Role of estradiol and antiestrogen », *Endocrinology*, vol. 103, 1978, p. 1742-1751.

par.: *Un effet estrogénique avec...*

FERRAZZI, E., CARTEI, G., MATTARAZZO, R. *et al.* « Oestrogen-like effect of tamoxifen on vaginal epithelium », *British Medical Journal*, vol. 1, 1977, p. 1351-1352.

NICHOLSON, R. I., GOTTING, K. E., GEE, J. *et al.* « Actions of oestrogens and antioestrogens on rat mammary gland development: Relevance to breast cancer prevention », *Journal of Steroid Biochemistry*, vol. 30, 1988, p. 95-103.

P. 186 par.: *Comme l'estradiol-17 β , le...*

HORWITZ, K. B., KOSEKI, Y. et MCGUIRE, W. L. « Estrogen control of progesterone receptor in human breast cancer: Role of estradiol and antiestrogen », *Endocrinology*, vol. 103, 1978, p. 1742-1751.

P. 188 par.: *Plusieurs femmes ayant eu...*

TRINH, X.-B., PEETERS, F. et TJALMA, W. A. A. « The thoughts of breast cancer survivors regarding the need for starting hormone replacement therapy », *European Journal of Obstetrics & Gynecology and Reproductive Biology*, vol. 124, 2006, p. 250-253.

par.: *En 2004, la Société...*

LEA, R., BANNISTER, E., CASE, A. *et al.* « Recours à l'hormonothérapie substitutive après un traitement contre le cancer du sein. Directives cliniques de la SOGC », *Journal of Obstetrics and Gynaecology Canada*, vol. 26, 2004, p. 55-60.

par.: *De nombreuses études proposent...*

POWLES, T. J., HICKISH, T., CASEY, S. *et al.* « Hormone replacement after breast cancer », *Lancet*, vol. 342, 1993, p. 60-61.

WILE, A. G., OPFELL, R. W. et MARGILETH, D. A. « Hormone replacement therapy in previously treated breast cancer patients », *American Journal of Surgery*, vol. 165, 1993, p. 372-375.

DISAIA, P. J., GROSEN, E. A., ODICINO, F. *et al.* « Replacement therapy for breast cancer survivors », *Cancer*, vol. 76, 1995, p. 2075-2078.

EDEN, J., BUSH, T., NAND, S. *et al.* « A case controlled study of combined continuous oestrogen-progesterone replacement therapy among women with a personal history of breast cancer », *Menopause*, vol. 2, 1995, p. 67-72.

DISAIA, P. J., GROSEN, E. A., KUROSAKI, T. *et al.* « Hormone replacement therapy in breast cancer survivors: A cohort study », *American Journal of Obstetrics and Gynecology*, vol. 174, 1996, p. 1494-1498.

DISAIA, P. J. « Estrogen replacement therapy for the breast cancer survivor: A reappraisal », *Journal of Surgical Oncology*, vol. 64, 1997, p. 175-180.

VASSILOPOULOU-SELLIN, R., THERIAULT, R. et KLEIN, M. J. « Estrogen replacement therapy in women with prior diagnosis and treatment for breast cancer », *Gynecologic Oncology*, vol. 65, 1997, p. 89-93.

DEW, J., EDEN, J., BELLER, E. *et al.* « A cohort study of hormone replacement therapy given to women previously treated for breast cancer », *Climacteric*, vol. 1, 1998, p. 137-142.

STOLL, B. A. et PARBHOO, S. « Treatment of menopausal symptoms in breast cancer patients », *Lancet*, vol. 1, 1988, p. 1278-1279.

BREWSTER, W. R., DISAIA, P. J., GROSEN, E. A. *et al.* « An experience with estrogen replacement therapy in breast cancer survivors », *International Journal of Fertility and Women's Medicine*, vol. 44, 1999, p. 186-192.

MAHAVNI, V. et BULLER, R. E. « Estrogen replacement therapy in endometrial and breast cancer survivors », *Clinical Obstetrics and Gynecology*, vol. 42, 1999, p. 863-875.

NATRAJAN, P. K., SOUMAKIS, K. et GAMBRELL, J.-R. R. D. « Estrogen replacement therapy in women with previous breast cancer », *American Journal of Obstetrics and Gynecology*, vol. 181, 1999, p. 288-295.

URSIC-VRSCAJ, M. et BEBAR, S. « A case-control study of hormone replacement therapy after primary surgical breast cancer treatment », *European Journal of Surgical Oncology*, vol. 25, 1999, p. 146-151.

VASSILOPOULOU-SELLIN, R., ASMAR, L., HORTOBAGYI, G. N. *et al.* « Estrogen replacement therapy after localized breast cancer: Clinical outcome of 319 followed prospectively », *Journal of Clinical Oncology*, vol. 17, 1999, p. 1482-1487.

DISAIA, P. J., BREWSTER, W. R., ZIOGAS, A. *et al.* « Breast cancer survival and hormone replacement therapy: A cohort analysis », *American Journal of Clinical Oncology*, vol. 23, 2000, p. 541-545.

BECKMANN, M. W., JAP, D., DJAHANSOUZI, S. *et al.* « Hormone replacement therapy after treatment of breast cancer: Effects on postmenopausal symptoms, bone mineral density and recurrence rates », *Oncology*, vol. 60, 2001, p. 199-206.

COL, N. F., HIROTA, L. K., ORR, R. K. *et al.* « Hormone replacement therapy after breast cancer: A systematic review and quantitative assessment of risk », *Journal of Clinical Oncology*, vol. 19, 2001, p. 2357-2363.

O'MEARA, E. S., ROSSING, M. A., DALING, J. R. *et al.* « Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality », *Journal of the National Cancer Institute*, vol. 93, 2001, p. 754-762.

par. : *Par exemple, lors...*

EDEN, J. « Should women who have had breast cancer take hormone replacement therapy? », *Maturitas*, vol. 22, 1995, p. 69-70.

EDEN, J., BUSH, T., NAND, S. *et al.* « A case controlled study of combined continuous oestrogen-progesterone replacement therapy among women with a personal history of breast cancer », *Menopause*, vol. 2, 1995, p. 67-72.

par. : *Une autre étude importante...*

DEW, J., EDEN, J., BELLER, E. *et al.* « A cohort study of hormone replacement therapy given to women previously treated for breast cancer », *Climacteric*, vol. 1, 1998, p. 137-142.

par.: *Une synthèse des articles...*

MAHAVNI, V. et BULLER, R. E. « Estrogen replacement therapy in endometrial and breast cancer survivors », *Clinical Obstetrics and Gynecology*, vol. 42, 1999, p. 863-875.

P. 189 par.: *Une étude menée par...*

O'MEARA, E. S., ROSSING, M. A., DALING, J. R. *et al.* « Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality », *Journal of the National Cancer Institute*, vol. 93, 2001, p. 754-762.

par.: *Récemment, trois études randomisées...*

HOLMBERG, L. et ANDERSON, H., pour les comités HABITS. « HABITS (hormonal replacement therapy after breast cancer – is it safe ?), a randomised comparison: Trial stopped », *Lancet*, vol. 363, 2004, p. 453-455.

XYDAKIS A.M., SAKKAS E. GR., MASTORAKOS G. « Hormone replacement therapy in breast cancer survivors », *Annals New York Academy of Sciences*, vol. 1092, 2006, p. 349-360.

par.: *Pendant près de 60...*

SEGALOFF, A. « Progress report: Results of studies by the Cooperative Breast Cancer Group – 1956-1960 », *Cancer Chemotherapy Reports*, vol. 11, 1961, p. 109-141.

KENNEDY, B. J. « Massive estrogen administration in premenopausal women with metastatic breast cancer », *Cancer*, vol. 15, 1962, p. 641-648.

SEGALOFF, A. « Cooperative Breast Cancer Group », *Cancer Chemotherapy Reports*, vol. 41, 1964, supplément.

HILF, R., MICHEL, I. et BELL, C. « Biochemical and morphological responses of normal and neoplastic mammary tissue to hormonal treatment », *Recent Progress in Hormone Research*, vol. 23, 1967, p. 229-295.

Revue dans LONNING, P. E., TAYLOR, P. D., ANKER, G. *et al.* « High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy », *Breast Cancer Research and Treatment*, vol. 67, 2001, p. 111-116.

par.: *Plus récemment, des chercheurs...*

LONNING, P. E., TAYLOR, P. D., ANKER, G. *et al.* « High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy », *Breast Cancer Research and Treatment*, vol. 67, 2001, p. 111-116.

P. 190 par.: *Des recherches chez des...*

HILF, R., MICHEL, I. et BELL, C. « Biochemical and morphological responses of normal and neoplastic mammary tissue to hormonal treatment », *Recent Progress in Hormone Research*, vol. 23, 1967, p. 229-295.

par.: *L'effet anticancer des...*

SEGALOFF, A. « Hormones and breast cancer », *Recent Progress in Hormone Research*, vol. 22, 1966, p. 351-379.

par.: *D'autres chercheurs ont...*

LIPPMAN, M., BOLAN, G. et HUFF, K. « The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture », *Cancer Research*, vol. 36, 1976, p. 4595-4601.

LIPPMAN, M., BOLAN, G. et HUFF, K. « The effects of glucocorticoids and progesterone on hormone-responsive human breast cancer in long-term tissue culture », *Cancer Research*, vol. 36, 1976, p. 4602-4609.

P. 191 par.: *Anastasia avait repris les...*

SONG, R. X.-D., MOR, G., NAFTOLIN, F. *et al.* « Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17 β -estradiol », *Journal of the National Cancer Institute*, vol. 93, 2001, p. 1714-1723.

par.: *Des chercheurs en oncologie...*

MAURIAC, L. et DEBLED, M. *Quel traitement anti-hormonal après hormonothérapie adjuvante par inhibiteur de l'aromatase*, Paris, Eurocancer, John Libbey Eurotext, 2006, p. 189-190.

par.: *En résumé, toutes ces...*

Revue dans SANTEN, R. J., SONG, R. X., ZHANG, Z. *et al.* « Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity », *Endocrine-Related Cancer*, vol. 12 (suppl. 1), 2005, p. S61-S73.

KATZENELLENBOGEN B.S., KENDRA K.L., NORMAN M.J. *et al.* « Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens », *Cancer Research*, vol. 47, 1987, p. 4355-4360.

tabl.: *Déficit en estradiol et...*

Revue dans SANTEN, R. J., SONG, R. X., ZHANG, Z. *et al.* « Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity », *Endocrine-Related Cancer*, vol. 12 (suppl. 1), 2005, p. S61-S73.

LEWIS, S., LOCKER, A., TODD, J.H. *et al.* « Expression of epidermal growth factor receptor in breast carcinoma », *Journal of Clinical Pathology*, vol. 43, 1990, p. 385-389.

POUTANEN, M., ISOMAA, V., PELTOKETO, H. *et al.* « Role of 17 β -hydroxysteroid dehydrogenase type 1 in endocrine and intracrine estradiol biosynthesis », *The Journal of Steroid Biochemistry and Molecular Biology*, vol. 55, 1995, p. 525-532.

P. 192 par.: *L'estriol provient de...*

FLOOD, C., PRATT, J.H., LONGCOPE, C. *et al.* « The metabolic clearance and blood production rates of estriol in normal, non-pregnant women », *Journal of Clinical Endocrinology & Metabolism*, vol. 42, 1976, p. 1-8.

par.: *À la suite de...*

LEMON, H. M. « Estriol prevention of mammary carcinoma induced by 7,12-dimethylbenzanthracene and procarbazine », *Cancer Research*, vol. 35, 1975, p. 1341-1353.

par.: *L'estriol pourrait aussi...*

Rapporté dans FOLLINGSTAD, A. H. « Estriol, the forgotten estrogen ? », *The Journal of the American Medical Association*, vol. 239, 1978, p. 29-30.

P. 193 par.: *En effet, des chercheurs...*

HUGGINS, C., TORRALBA, Y. et MAINZER, K. « Hormonal influences on mammary tumors of the rat. I. Acceleration of growth of transplanted fibroadenoma in ovariectomized and hypophysectomized rats », *Journal of Experimental Medicine*, vol. 104, 1956, p. 525-538.

par.: *De façon concordante, des...*

ANDERSON, J. N., CLARK, J. H. et PECK, E. J. J.-R. « The relationship between nuclear receptor-estrogen binding and uterotrophic responses », *Biochemical and Biophysical Research Communications*, vol. 48, 1972, p. 1460-1468.

ANDERSON, J. N., PECK, E. J. J.-R. et CLARK, J. H. « Estrogen-induced uterine responses and growth: Relationship to receptor estrogen binding by uterine nuclei », *Endocrinology*, vol. 96, 1975, p. 160- 167.

tabl.: *Pour en savoir plus...*

LEMON, H. M., WOTIZ, H. H., PARSONS, L. *et al.* « Reduced estriol excretion in patients with breast cancer prior to endocrine therapy », *The Journal of the American Medical Association*, vol. 196, 1966, p. 112-120.

LONGCOPE, C. « Breast cancer and estriol dynamics (abstr.) », *Program of the Breast Cancer Task Force*, 1975, p. 148.

BULBROOK, R. D., SWAIN, M. C., WANG, D. Y. *et al.* « Breast cancer in Britain and Japan: Plasma oestradiol-17 β , oestrone and progesterone, and their urinary metabolites in normal British and Japanese women », *European Journal of Cancer*, vol. 12, 1976, p. 725-735.

BULBROOK, R. D., MOORE, J. W., CLARK, G. M. G. *et al.* « Plasma oestradiol and progesterone levels in women with varying degrees of risk of breast cancer », *European Journal of Cancer*, vol. 14, 1978, p. 1369-1375.

MACMAHON, B., COLE, P., BROWN, J. B. *et al.* « Oestrogen profiles of Asian and North American women », *Lancet*, vol. 2, 1971, p. 900-903.

DICKINSON, L. E., MACMAHON, B., COLE, P. *et al.* « Estrogen profiles of Oriental and Caucasian women in Hawaii », *The New England Journal of Medicine*, vol. 292, 1974, p. 1211.

P. 194 par.: *Des recherches montrent aussi...*

DESHPANDE, N., CARSON, P., HORNER, J. « Oestriol in human breast tumours », *Journal of Steroid Biochemistry*, vol. 7, 1976, p. 11-13.

par.: *Nous avons vu que...*

COWAN, L. D., GORDIS, L., TONASCIA, J. A. *et al.* « Breast cancer incidence in women with a history of progesterone deficiency », *American Journal of Epidemiology*, vol. 114, 1981, p. 209-217.

par.: *L'étude a montré...*

MOHR, P. E., WANG, D.Y., GREGORY, W. M. *et al.* « Serum progesterone and prognosis in operable breast cancer », *British Journal of Cancer*, vol. 73, 1996, p. 1552-1555.

P. 195 tabl.: *Saviez-vous que...*

INOH, A., KAMIYA, K., FUJII, Y. *et al.* « Protective effects of progesterone and tamoxifen in estrogen-induced mammary carcinogenesis in ovariectomized W/Fu rats », *Japanese Journal of Cancer Research*, vol. 76, 1985, p. 699-704.

par.: *En effet, les cancers...*

ARPINO, G., WEISS, H., LEE, A. V. *et al.* « Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance », *Journal of the National Cancer Institute*, vol. 97, 2005, p. 1254-1261.

par.: *Par exemple, des chercheurs...*

CLARK, G. M., McGUIRE, W. L., HUBAY, C. A. *et al.* « Progesterone receptors as a prognostic factor in Stage II breast cancer », *The New England Journal of Medicine*, vol. 309, 1983, p. 1343-1347.

par.: *La présence ou...*

Revue dans FUQUA, S. A. W., CUI, Y., LEE, A. V. *et al.* « Insights into the role of progesterone receptors in breast cancer », *Journal of Clinical Oncology*, vol. 23, 2005, p. 931-932.

BARDOU, V. J., ARPINO, G., ELLEDGE, R. M. *et al.* « Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases », *Journal of Clinical Oncology*, vol. 21, 2003, p. 1973-1979.

par.: *En d'autres mots...*

CUI, X., ZHANG, P., DENG, W. *et al.* « Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: Progesterone receptor as a potential indicator of growth factor activity in breast cancer », *Molecular Endocrinology*, vol. 17, 2003, p. 575-588.

P. 196 par.: *Des chercheurs ont observé...*

LIN, V. C. L., ENG, A. S., HEN, N. E. *et al.* « Effect of progesterone on the invasive properties and tumor growth of progesterone receptor-transfected breast cancer cells MDA-MB-231 », *Clinical Cancer Research*, vol. 7, 2001, p. 2880-2886.

LEO, J.C.L., WANG, S.M., GUO, C.H. *et al.* « Gene regulation profile reveals consistent anti-cancer properties of progesterone in hormone-independent breast cancer cells transfected with progesterone receptor », *International Journal of Cancer*, vol. 117, 2005, p. 561-568.

par.: *Cette inhibition de la...*

LEO, J.C.L., WANG, S.M., GUO, C.H. *et al.* « Gene regulation profile reveals consistent anti-cancer properties of progesterone in hormone-independent breast cancer cells transfected with progesterone receptor », *International Journal of Cancer*, vol. 117, 2005, p. 561-568.

par.: *Des recherches ont montré...*

FORMBY, B. et WILEY, T. S. « Progesterone inhibits growth and induces apoptosis in breast cancer cells: Inverse effects on Bcl-2 and p53 », *Annals Clinical Laboratory Science*, vol. 28, 1998, p. 360-369.

par.: *Une étude avec des...*

HORWITZ, K. B. et McGUIRE, W. L. « Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor », *Journal of Biological Chemistry*, vol. 253, 1978, p. 2223-2228.

par.: *Selon moi, la progestérogène...*

ALKHALAF, M. et EL-MOWAFY, A. M. « Overexpression of wild-type p53 gene renders MCF-7 breast cancer cells more sensitive to the antiproliferative effect of progesterone », *Journal of Endocrinology*, vol. 179, 2003, p. 55-62.

P. 197 par.: *La progestérogène exercerait un...*

LEO, J.C.L., WANG, S.M., GUO, C.H. *et al.* « Gene regulation profile reveals consistent anti-cancer properties of progesterone in hormone-independent breast cancer cells transfected with progesterone receptor », *International Journal of Cancer*, vol. 117, 2005, p. 561-568.

- P. 198 par.: *Une des stratégies pour...*
LIN, V. C. L., ENG, A. S., HEN, N. E. *et al.* « Effect of progesterone on the invasive properties and tumor growth of progesterone receptor-transfected breast cancer cells MDA-MB-231 », *Clinical Cancer Research*, vol. 7, 2001, p. 2880-2886.
- P. 200 par.: *Une étude concernant les...*
RICHARDS, J. B., PAPAIOANNOU, A., ADACHI, J. D. *et al.* « Effect of selective serotonin reuptake inhibitors on the risk of fracture », *Archives of Internal Medicine*, vol. 167, 2007, p. 188-194.
- P. 201 par.: *Je ne suis pas...*
LEE, J. S. *Raloxifene may lower stroke risk in some postmenopausal women*, International Stroke Conference, Orlando, 17 février 2006, extrait LB2.
LEE, J.-S. Rapporté dans *L'Actualité médicale*, 12 avril 2006, p. 27.
LEE, J.-S. Rapporté dans *The Medical Post*, 14 mars 2006, p. 17.
- P. 202 par.: *D'ailleurs, on sait...*
BROWNER, W. S., PRESSMAN, A. R., NEVITT, M. C. *et al.* « Association between low bone density and stroke in elderly women. The study of osteoporotic fractures », *Stroke*, vol. 24, 1993, p. 940-946.
- P. 203 par.: *Plusieurs croient que cette...*
HODGES D. « Link between HRT, breast CA "remarkable" », Rapporté dans *The Medical Post*, 1^{er} mai 2007.
par.: *Cependant, ces données ne...*
DISAIA, P. J. « Estrogen replacement therapy for the breast cancer survivor: A reappraisal », *Journal of Surgical Oncology*, vol. 64, 1997, p. 175-180.
- P. 205 tabl.: *Saviez-vous que...*
Revue dans WREN, B. G. « Do female sex hormones initiate breast cancer? A review of the evidence », *Climacteric*, vol. 7, 2004, p. 120-128.
- P. 206 par.: *Une analyse des résultats...*
Revue dans *Geriatrics & Aging*, vol. 9 (supplément), 2006, p. 23-28.
- P. 207 par.: *Des biopsies de la...*
MARKS, L. S., MAZER, N. A., MOSTAGHEL, E. *et al.* Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism. *The Journal of the American Medical Association*, vol. 296, 2006, p. 2351-2361.
par.: *Le D^r Abraham Morgentaler...*
MORGATENLER, A. Rapporté dans *The Medical Post*, 6 mars 2007, p. 21.
- P. 208 par.: *En effet, une lecture...*
Revue dans SCHILDKRAUT, J. M., CALINGAERT, B., MARCHBANKS, P. A. *et al.* « Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk », *Journal of the National Cancer Institute*, vol. 94, 2002, p. 32-38.

par.: *Les contraceptifs oraux entraîneraient...*

Revue dans SCHILDKRAUT, J. M., CALINGAERT, B., MARCHBANKS, P. A. *et al.* « Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk », *Journal of the National Cancer Institute*, vol. 94, 2002, p. 32-38.

par.: *Les chercheurs ont remarqué...*

SCHILDKRAUT, J. M., CALINGAERT, B., MARCHBANKS, P. A. *et al.* « Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk », *Journal of the National Cancer Institute*, vol. 94, 2002, p. 32-38.

par.: *Récemment, une étude...*

RODRIGUEZ, G. C., WALMER, D. K., CLINE, M. *et al.* « Effect of progestin on the ovarian epithelium of macaques: Cancer prevention through apoptosis? », *Journal of the Society for Gynecologic Investigation*, vol. 5, 1998, p. 271-276.

P. 209 tabl.: *Le cancer des ovaires...*

MILLION WOMEN STUDY COLLABORATORS. « Ovarian cancer and hormone replacement therapy in the Million Women Study », *Lancet*, vol. 369, 2007, p. 1703-1710.

par.: *Des chercheurs ont évalué...*

COOPER, D. R. et BUTTERFIELD, J. « Pregnancy subsequent to mastectomy for cancer of the breast », *Annals of Surgery*, vol. 171, 1970, p. 429-433.

RIBIERO, G., JONES, D. A. et JONES, M. « Carcinoma of the breast associated with pregnancy », *British Journal of Surgery*, vol. 73, 1986, p. 607-609.

KROMAN, N., JENSEN, M.-B., MELBYE, M. *et al.* « Should women be advised against pregnancy after breast-cancer treatment? », *Lancet*, vol. 350, 1997, p. 319-322.

P. 210 par.: *Une étude, récemment publiée...*

IVES, A., SAUNDERS, C., BULSARA, M. *et al.* « Pregnancy after breast cancer: Population based study », *British Medical Journal*, vol. 334, 2007, p. 194-198.

par.: *Dans une recherche non...*

KREIGER, N., SLOAN, M., COTTERCHIO, M. *et al.* « The risk of breast cancer following reproductive surgery », *European Journal of cancer*, vol. 35, 1999, p. 97-101.

par.: *D'ailleurs, une étude...*

RAVDIN, R. G., LEWISON, E. F., SLACK, N. H. *et al.* « Results of a clinical trial concerning the worth of prophylactic oophorectomy for breast carcinoma », *Surgery Gynecology And Obstetrics*, vol. 131, 1970, p. 1055-1064.

P. 211 tabl.: *Le cancer du sein...*

MOTE, P. A., LEARY, J. A., AVERY, K. A. *et al.* « Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A », *Genes Chromosomes Cancer*, vol. 39, 2004, p. 236-248.

par.: *Les résultats d'une...*

ROCCA, W.A., GROSSARDT B.R., DEANDRADE M. *et al.* « Survival patterns after oophorectomy in premenopausal women: A population-based cohort study », *Lancet Oncology* vol. 7, 2006, p. 821-828.

- P. 212 par.: *De plus, le nombre...*
Revue dans KODAMA, M., KODAMA, T., MIURA, S. *et al.* « Nature of ovarian-adrenal dysfunction in breast cancer patients », *Journal of the National Cancer Institute*, vol. 63, 1979, p. 599-608.
- P. 214 par.: *Certains d'entre vous...*
MAILLOUX, P. et BEAULIEU, J. *Pour la castration volontaire des pédophiles*, Québec, VLB éditeur, 2001, 91 p.
- P. 215 par.: *Des chercheurs ont estimé...*
PARKER *et al.* Rapporté dans *The Medical Post*, 14 juin 2005.
ROCCA, W.A., GROSSARDT B.R., DEANDRADE M. *et al.* « Survival patterns after oophorectomy in premenopausal women: A population-based cohort study », *Lancet Oncology* vol. 7, 2006, p. 821-828.
- P. 221 par.: *Par exemple, l'AMP...*
BAMBERGER, C. M., ELSE, T., BAMBERGER, A. M. *et al.* « Dissociative glucocorticoid activity of medroxyprogesterone acetate in normal human lymphocytes », *Journal of Clinical Endocrinology & Metabolism*, vol. 84, 1999, p. 4055-4061.
par.: *Des expériences ont aussi...*
HORWITZ, K. B., MOCKUS, M. B., PIKE, A. W. *et al.* « Progesterone receptor replenishment in T47D human breast cancer cells. Roles of protein synthesis and hormone metabolism », *Journal of Biological Chemistry*, vol. 258, 1983, p. 7603-7610.
MOCKUS, M. B. et HORWITZ, K. B. « Progesterone receptors in human breast cancer. Stoichiometric translocation and nuclear receptor processing », *Journal of Biological Chemistry*, vol. 258, 1983, p. 4778-4783.
- P. 222 tabl.: *Saviez-vous que...*
MINSHALL, R. D., STANCZYK, F. Z., MIYAGAWA, K. *et al.* « Ovarian steroid protection against coronary artery hyperreactivity in rhesus monkeys », *Journal of Clinical Endocrinology & Metabolism*, vol. 83, 1998, p. 649-659.
par.: *Contrairement aux progestines, la...*
FENNESSEY, P. V., PIKE, A. W., GONZALEZ-ALLER, C. *et al.* « Progesterone metabolism in T47D [co] human breast cancer cells-I. 5 α -Pregnan-3 β , 6 α -diol-20-one is the secreted product », *Journal of Steroid Biochemistry*, vol. 25, 1986, p. 641-648.
par.: *Par exemple, l'AMP...*
The Writing Group for the PEPI trial. « Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial », *The Journal of the American Medical Association*, vol. 273, 1995, p. 199-208.
WILLIAMS, J. K., HONORÉ, E. K., WASHBURN, S. A. *et al.* « Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys », *Journal of the American College of Cardiology*, vol. 24, 1994, p. 1757-1761.
MIYAGAWA, K., RÖSCH, J., STANCZYK, F. *et al.* « Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm », *Nature Medicine*, vol. 3, 1997, p. 324-327.

SARREL, P. M. «The differential effects of oestrogens and progestins on vascular tone », *Human Reproduction Update*, vol. 5, 1999, p. 205-209.

ROSANO, G. M. C., WEBB, C. M., CHIERCHIA, S. *et al.* « Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women », *Journal of the American College of Cardiology*, vol. 36, 2000, p. 2154-2159.

par.: *Curieusement, les propriétés de...*

BURRIS T.P. et KRISHNAN V. « Estrogen: A mitochondrial energizer that keeps on going », *Molecular Pharmacology*, vol. 68, 2005, p. 956-958.

P. 225 tabl.: *Selon moi...*

YEN S.S.C., MARTIN P.L., BURNIER A.M. *et al.* « Circulating estradiol, estrone and gonadotropin levels following the administration of orally active 17 β -estradiol in postmenopausal women », *Journal of Clinical Endocrinology & Metabolism*, vol. 40, 1975, p. 518-521.

POWERS, M. S., SCHENKEL, L., DARLEY, P. E. *et al.* « Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17 β -estradiol: Comparison with conventional oral estrogens used for hormone replacement », *American Journal of Obstetrics and Gynecology*, vol. 152, 1985, p. 1099-1106.

SCOTT, R. T. J.-R., ROSS, B., ANDERSON, C. *et al.* « Pharmacokinetics of percutaneous estradiol: A cross-over study using a gel and a transdermal system in comparison with oral micronized estradiol », *Obstetrics & Gynecology*, vol. 77, 1991, p. 758-764.

P. 227 par.: *Par exemple, certains chercheurs...*

ADAMS, M. R., KAPLAN, J. R., MANUCK, S. B. *et al.* « Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone », *Arteriosclerosis*, vol. 10, 1990, p. 1051-1057.

GIBBS, R. B. et GABOR, R. « Estrogen and cognition: Applying preclinical findings to clinical perspectives », *Journal of Neuroscience Research*, vol. 74, 2003, p. 637-643.

par.: *Cependant, la dose de...*

HANKE, H., HANKE, S., BRUCK, B. *et al.* « Inhibition of the protective effect of estrogen by progesterone in experimental atherosclerosis », *Atherosclerosis*, vol. 121, 1996, p. 129-138.

P. 229 par.: *Des études indiquent plutôt...*

O'LEARY, P., FEDDEMA, P., CHAN, K. *et al.* « Salivary, but not serum or urinary levels of progesterone are elevated after topical application of progesterone cream to pre- and postmenopausal women », *Clinical Endocrinology*, vol. 53, 2000, p. 615-620.

par.: *Des chercheurs ont observé...*

CAREY, B. J., CAREY, A. H., PATEL, S. *et al.* « A study to evaluate serum and urinary hormone levels following short and long term administration of two regimens of progesterone cream in postmenopausal women », *British Journal of Obstetrics and Gynaecology*, vol. 107, 2000, p. 722-726.

COOPER, A., SPENCER, C., WHITEHEAD, M.I. *et al.* « Systemic absorption of progesterone from Progest cream in postmenopausal women », *Lancet*, vol. 351, 1998, p. 1255-1256.

- P. 230 tabl. : *Saviez-vous que...*
 Revue dans NACHTIGALL, L. E., RAJU, U., BANERJEE, S. *et al.* « Serum estradiol-binding profiles in postmenopausal women undergoing three common estrogen replacement therapies: Associations with sex hormone-binding globulin, estradiol, and estrone levels », *Meno-pause*, vol. 7, 2000, p. 243-250.
- P. 231 par. : *Il faut aussi savoir...*
 STREL'CHYONOK, O. A., AVVAKUMOV, G. V. et SURVILO, L. I. « A recognition system for sex-hormone-binding protein-estradiol complex in human decidual endometrium plasma membranes », *Biochimica et Biophysica Acta*, vol. 802, 1984, p. 459-466.
 ROSNER, W., HRYB, D. J., KHAN, M. S. *et al.* « Sex hormone-binding globulin. Binding to cell membranes and generation of a second messenger », *Journal of Andrology*, vol. 13, 1992, p. 101-106.
 Revue dans WHITE, R. E., DARKOW, D. J. et FALVO LANG, J. L. « Estrogen relaxes coronary arteries by opening BKCa channels through a cGMP-dependent mechanism », *Circulation Research*, vol. 77, 1995, p. 936-942.
 Revue dans NACHTIGALL, L. E., RAJU, U., BANERJEE, S. *et al.* « Serum estradiol-binding profiles in postmenopausal women undergoing three common estrogen replacement therapies: Associations with sex hormone-binding globulin, estradiol, and estrone levels », *Meno-pause*, vol. 7, 2000, p. 243-250.
 par. : *Seriez-vous surpris si...*
 CHOUDHRY, N. K., STELFOX, H. T. et DETSKY, A. S. « Relationships between authors of clinical practice guidelines and the pharmaceutical industry », *The Journal of the American Medical Association*, vol. 287, 2002, p. 612-617.
- P. 238 par. : *Une expérience faite chez...*
 LYDON, J. P. Projet de recherche : « The role of calcitonin, a progesterone-responsive gene, and the calcitonin receptor in mammary gland development and tumorigenesis », Baylor College of Medicine, United States, 2000.
 ISMAIL, P.M., DeMAYO, F. J., AMATO, P. *et al.* « Progesterone induction of calcitonin in the murine mammary gland », *Journal of Endocrinology*, vol. 180, 2004, p. 287-295.
- P. 239 tabl. : *Estrogènes et vitamine D*
 SORENSEN, O. H., LUND, B., LUND, B. *et al.* « Effects of 1, alpha vitamin D on bone and muscle in senile osteoporosis », dans McINTYRE, I. et SCELKE, J. (dir.). *Molecular endocrinology*, Amsterdam, Elsevier/North Holland, 1979, p. 309-318.
 STOCK, J. L., CODERRE, J. A. et MALLETTE, L. E. « Effects of a short course of estrogen on mineral metabolism in postmenopausal women », *Journal of Clinical Endocrinology & Metabolism*, vol. 61, 1985, p. 595-600.